var title_f27_43_28336="Seborrheic dermatitis face 2 PI";
var content_f27_43_28336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Facial seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28336=[""].join("\n");
var outline_f27_43_28336=null;
var title_f27_43_28337="Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)";
var content_f27_43_28337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/44/2755\">",
"         Patient information: Warfarin (Coumadin) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/15/21747\">",
"         Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Prothrombin time (PT) test and International Normalized Ratio (INR) (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H556655716\">",
"      <span class=\"h1\">",
"       What is a prothrombin time test and an International Normalized Ratio?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A prothrombin time test (also called a PT or &ldquo;pro time&rdquo; test) is a blood test that measures how long it takes your blood to clot.",
"     </p>",
"     <p>",
"      Different labs use different tests to measure PT. Because of this, your PT value must be changed to a standard number, called the International Normalized Ratio (INR). Your INR value tells your doctor if your blood is clotting too much or too little. This is true even if you get the test done in different lab (if you are travelling, for example).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H556655733\">",
"      <span class=\"h1\">",
"       Why do I need a PT test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You need regular PT tests if you take",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      (sample brand names Coumadin, Warfilone). This medicine helps prevent dangerous blood clots. Doctors prescribe it to people who might get blood clots or who have had a blood clot in the past.",
"     </p>",
"     <p>",
"      If you are NOT taking",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      , your doctor might test your PT if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You are going to have surgery",
"       </li>",
"       <li>",
"        Your have symptoms of a bleeding problem, such as nosebleeds, bleeding gums, or blood in your urine or bowel movements",
"       </li>",
"       <li>",
"        You have very heavy menstrual periods",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H556655748\">",
"      <span class=\"h1\">",
"       If I take warfarin, how often do I need a PT test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will likely get a PT test before you begin taking",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      . You will need another PT test the next day after you have taken 2 doses of warfarin.",
"     </p>",
"     <p>",
"      Your doctor will then adjust your",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      dose to get your INR level between 2.0 and 3.0. You might need PT tests every few days for a while, to make sure you&rsquo;re taking the right dose of warfarin. Once your INR level stays the same for at least 1 to 2 weeks, you can probably get PT tests just once a month.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H556655765\">",
"      <span class=\"h1\">",
"       Can I test my PT at home?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you will be taking",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      for a long time, you might be able to use a home monitor to test your PT at home.",
"     </p>",
"     <p>",
"      Talk to your doctor about whether you could use a home monitor.",
"     </p>",
"     <p>",
"      PT home testing machines are about the size of a small book. You poke your finger with a small, sharp object, then place a drop of blood on the special test strip in the machine. The readout on the machine shows your",
"      <span class=\"nowrap\">",
"       PT/INR",
"      </span>",
"      value.",
"     </p>",
"     <p>",
"      You then report the number to your doctor, who will tell you if you should change your",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      dose. This is called &ldquo;self-monitoring.&rdquo; Some people might be able to learn how to adjust their own warfarin dose. This is called &ldquo;self-management.&rdquo; Self-management is only for people who have been trained by a doctor or nurse and have shown that they know how to change their dose. Do NOT try self-management without the OK of your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H556655782\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/43/28337?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86639 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28337=[""].join("\n");
var outline_f27_43_28337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H556655716\">",
"      What is a prothrombin time test and an International Normalized Ratio?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H556655733\">",
"      Why do I need a PT test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H556655748\">",
"      If I take warfarin, how often do I need a PT test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H556655765\">",
"      Can I test my PT at home?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H556655782\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_43_28338="Candidal intertrigo neck folds";
var content_f27_43_28338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Candidal intertrigo in the neck folds of an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Symmetric, erythematous, weepy, and peeling skin folds of an infant with",
"    <em>",
"     Candida",
"    </em>",
"    intertrigo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Panagiotis Mitropoulos, DO. Originally published in: Mitropoulos P. Infant with red, peeling rashes. Am Fam Physician 2008; 77:1015. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28338=[""].join("\n");
var outline_f27_43_28338=null;
var title_f27_43_28339="Incising posterior cul de sac";
var content_f27_43_28339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incising the posterior pelvic cul-de-sac during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scissors are used to enter the vagina through the posterior cul-de-sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28339=[""].join("\n");
var outline_f27_43_28339=null;
var title_f27_43_28340="Angiogram coiled cerebral aneurysm";
var content_f27_43_28340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Aneurysm before and after therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Towne projection of an aneurysm of the right posterior cerebral artery before (left panel) and after (right panel) successful coil embolization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Guy Rordorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28340=[""].join("\n");
var outline_f27_43_28340=null;
var title_f27_43_28341="Organoaxial gastric volvulus";
var content_f27_43_28341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Organoaxial gastric volvulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain radiograph of the abdomen (A) shows a large central gas bubble in the thoracic cavity reminiscent of a large hiatal hernia (between white arrows). A barium study (B)&nbsp;shows the greater curvature of the stomach (red arrow) superior to the lesser curvature (blue arrow). These findings are characteristic of an organoaxial volvulus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28341=[""].join("\n");
var outline_f27_43_28341=null;
var title_f27_43_28342="Ethanol ablation HCM";
var content_f27_43_28342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Ethanol ablation in HCM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 655px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depiction of alcohol (ethanol) septal ablation. Infarction of the proximal interventricular septum is caused by infusion of ethanol into the first septal perforating branch of the left anterior descending coronary artery through an angioplasty catheter. The inset demonstrates a balloon occluding the septal branch during the ethanol infusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28342=[""].join("\n");
var outline_f27_43_28342=null;
var title_f27_43_28343="Bone biopsy and the diagnosis of renal osteodystrophy";
var content_f27_43_28343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bone biopsy and the diagnosis of renal osteodystrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28343/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28343/contributors\">",
"     L Darryl Quarles, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28343/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28343/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28343/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28343/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/43/28343/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five major types of bone disease that occur in patients with advanced chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Predominant hyperparathyroid-mediated high-turnover bone disease (osteitis fibrosa, OF)",
"     </li>",
"     <li>",
"      Low turnover osteomalacia (defective mineralization in association with low osteoclast and osteoblast activities)",
"     </li>",
"     <li>",
"      Mixed uremic osteodystrophy, or MUO (hyperparathyroid bone disease with a superimposed mineralization defect)",
"     </li>",
"     <li>",
"      Osteomalacia (defined as a mineralization lag time greater than 100 days).",
"     </li>",
"     <li>",
"      Adynamic bone (diminished bone formation and resorption)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    They are collectively called renal osteodystrophy.",
"   </p>",
"   <p>",
"    The pathogenesis of these disorders is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a 2006 position statement from KDIGO (Kidney Disease: Improving Global Outcomes), it was stated that the term, renal osteodystrophy, should be exclusively used to define bone morphology alterations observed in chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/5\">",
"     5",
"    </a>",
"    ]. These alterations can be assessed further by histomorphometry, including aspects of bone turnover, mineralization, and volume. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'TMV classification system'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    By comparison, the term chronic kidney disease-mineral and bone disorder was defined as a broader syndrome in those with chronic kidney disease, in which abnormalities in bone and mineral metabolism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extra-skeletal calcification are observed.",
"   </p>",
"   <p>",
"    However, these classifications do not adequately consider the clinically important outcome of bone disease in CKD, that is, the marked increase in fracture risk that is observed across all histological types.",
"   </p>",
"   <p>",
"    This topic will review the diagnostic distinction between the different types of renal bone disease with emphasis on the role of bone biopsy, which remains the gold standard to help diagnose renal osteodystrophy. Dialysis-related amyloidosis most commonly affects the synovia but can produce cystic lesions in the long bones that mimic the changes of hyperparathyroidism. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the traditional forms of renal bone disease is associated with characteristic histologic findings. Appreciation of these abnormalities is simpler if we first review the appearance of normal bone.",
"   </p>",
"   <p>",
"    Bone undergoes remodeling and bone diseases are classified based on alterations in osteoblast-mediated bone formation, osteoclast-mediated bone formation and mineralization of extracellular matrix.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal bone is composed of osteoid, which stains red&ndash;brown with the Goldner&ndash;Masson (trichrome) stain, and mineralized bone, which stains blue (",
"    <a class=\"graphic graphic_picture graphicRef66330 \" href=\"UTD.htm?28/13/28883\">",
"     picture 1",
"    </a>",
"    ). The osteoid appears orange and the mineralized bone is green in the Villanueva&ndash;stained section viewed under fluorescent light. The luminescent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    bands within bone represents active mineralized bone formation beneath the osteoid surface.",
"   </p>",
"   <p>",
"    The osteoid is lamellar, present on a modest amount of the bone surface (&lt;25 percent), and covered with mature osteoblasts (about 40 percent). Bone resorption is minimal (&lt;7 percent) and osteoclasts are present on a small percentage of the bone surface (&lt;2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Severe osteitis fibrosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic and often marked parathyroid hormone (PTH) excess leads to marrow fibrosis, woven osteoid, increased number and activity of osteoblasts, expansion of osteoid surfaces, and numerous osteoclasts and resorptive surfaces (",
"    <a class=\"graphic graphic_picture graphicRef63957 \" href=\"UTD.htm?31/5/31832\">",
"     picture 2",
"    </a>",
"    ). Distinct",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    labels cover the majority of bone surfaces, indicating accelerated bone formation and the absence of a mineralization defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mixed uremic osteodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed uremic osteodystrophy resembles osteitis fibrosa on light microscopy, except there is a greater degree of osteoid accumulation (",
"    <a class=\"graphic graphic_picture graphicRef52703 \" href=\"UTD.htm?19/57/20376\">",
"     picture 3",
"    </a>",
"    ). However, fluorescent evaluation shows impaired mineralization, as evidenced by diffuse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    deposition and the absence of tetracycline in some bone forming surfaces. There is also a decreased mineralization lag time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Low turnover osteomalacia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low turnover osteomalacia, as opposed to the high turnover form in mixed uremic osteodystrophy, is characterized by a marked increase in the fraction of bone exhibiting wide osteoid seams and the absence of osteoblasts or erosive surfaces (",
"    <a class=\"graphic graphic_picture graphicRef61773 \" href=\"UTD.htm?0/32/520\">",
"     picture 4",
"    </a>",
"    ). Examination under fluorescent light reveals little or no",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    deposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adynamic bone disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adynamic or aplastic bone disorder, a disorder of increasing incidence, is characterized by reductions in both bone formation and resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These defects are manifested histologically by thin osteoid seams that display no active mineralization, inactive appearing osteoblasts, and decreases in osteoclast number and bone resorptive surfaces (",
"    <a class=\"graphic graphic_picture graphicRef75592 \" href=\"UTD.htm?30/56/31623\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Affected patients usually have normal or only minimally elevated serum PTH concentrations (see below), a propensity to develop hypercalcemia due to decreased calcium deposition in bone, and may be at a markedly increased risk for hip fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In children, the adynamic bone disorder is associated with reduced growth rates even compared to other forms of renal osteodystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Aluminum deposition in bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aluminum-induced bone disease is now much less frequently observed due to the use of water purification for dialysate solutions and the substitution of calcium salts and other compounds for aluminum-containing antacids to bind intestinal phosphate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .) When it occurs, there is extensive aluminum deposition on bone surfaces in osteomalacia; bone aluminum deposition also occurs in a small percentage of patients with adynamic bone disease. Aluminum can be detected histologically with a Villanueva&ndash;prestained section stained with aurintricarboxylic acid (",
"    <a class=\"graphic graphic_picture graphicRef65065 \" href=\"UTD.htm?4/21/4434\">",
"     picture 6",
"    </a>",
"    ). The osteoid is light blue and the mineralized bone is white. Aluminum stains as a red band at the osteoid&ndash;bone interface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     TMV classification system",
"    </span>",
"    &nbsp;&mdash;&nbsp;To help clarify the interpretation of the bone biopsy, a 2006 National Kidney Foundation (NKF) working group on renal osteodystrophy published a position paper that suggested that renal bone disease should be characterized by three key histologic descriptors: turnover, mineralization, and volume [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Turnover, which may be low, normal, or high",
"     </li>",
"     <li>",
"      Mineralization, which may be normal or abnormal",
"     </li>",
"     <li>",
"      Volume, which may be low, normal, or high",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is termed the TMV classification system: Although unproven, this system, which is consistent with the commonly used classification system previously described, was created to help define the pathophysiology of renal bone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tests are useful in the evaluation of patients suspected of having renal osteodystrophy. Included in this group are serum calcium, phosphorous, PTH and alkaline phosphatase (total or bone specific) levels, imaging studies, the desferoxamine challenge test, and bone biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum intact PTH concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating intact PTH levels predict the presence and severity of hyperparathyroidism; they may not, however, predict underlying bone disease, particularly when PTH levels are only moderately elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/3,4,9-12\">",
"     3,4,9-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=see_link\">",
"     \"Parathyroid hormone assays and their clinical use\"",
"    </a>",
"    .) for a brief review of the different available PTH assays and (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Bone biopsy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Thus, PTH levels are generally insufficient to establish the type of renal osteodystrophy. Guidelines for the use of intact PTH levels are [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intact serum PTH values below 100",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      are associated with a decreased likelihood of osteitis fibrosa and an increased incidence of adynamic bone disease.",
"     </li>",
"     <li>",
"      An intact serum PTH level above 450",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      is typically associated with hyperparathyroid bone disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mixed uremic osteodystrophy.",
"     </li>",
"     <li>",
"      Intermediate PTH levels between 100 and 450",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      may be associated with normal, elevated bone remodeling, or even reduced bone remodeling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intact PTH values below 200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    may be associated with a markedly increased risk of fracture. In one study of over 1,000 dialysis patients, the incidence of hip fracture, compared to that observed in the general population, was 14 and 17 times greater for men and women with end-stage renal disease (ESRD), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/7\">",
"     7",
"    </a>",
"    ]. Multivariate analysis revealed that a serum PTH concentration less than 195",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    significantly predicted fracture risk. Although not confirmed by bone biopsy, such values were likely to be associated with adynamic bone disease.",
"   </p>",
"   <p>",
"    The intact assays just described use antisera directed toward the inactive mid-or carboxyterminal part of the PTH molecule. They therefore detect the intact as well as several of the inactive moieties of PTH.",
"   </p>",
"   <p>",
"    The development of newer immunoradiometric assays, which detect the biologically active PTH 1-84, offer the possibility of enhanced standardization. Although these second generation assays may be the optimal tests for assessing abnormal parathyroid hormone dynamics, practically all of the data related to renal osteodystrophy are based upon levels derived from the intact PTH assay. The National Kidney Foundation Dialysis Outcome Quality Initiative",
"    <span class=\"nowrap\">",
"     (NKF/DOQI)",
"    </span>",
"    guidelines currently state that is premature to rely clinically on the newer assays. If used, the second generation assays appear to provide values that are approximately 50 to 60 percent of those achieved with the intact assays.",
"   </p>",
"   <p>",
"    Issues related to the properties of different PTH assays are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=see_link\">",
"     \"Parathyroid hormone assays and their clinical use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Alkaline phosphatase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other markers of osteoblast&ndash;mediated bone formation, such as bone-specific or total alkaline phosphatase, may provide useful information in conjunction with PTH measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of a low serum bone-specific alkaline phosphatase concentration (&le;7",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      and a low serum PTH is suggestive of a low remodeling disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An elevated serum bone-specific alkaline phosphatase (&ge;20",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      alone or in combination with increased serum PTH (above 200",
"      <span class=\"nowrap\">",
"       pg/mL),",
"      </span>",
"      appears to be highly sensitive and specific for high turnover bone disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although bone-specific alkaline phosphatase may provide some advantages, some experts feel that total serum alkaline phosphatase plus PTH levels are adequate in assessing bone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147942744\">",
"    <span class=\"h2\">",
"     Biochemical markers of bone resorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred biochemical marker of bone resorption among patients with normal kidney function, serum C-telopeptide of type I collagen (CTX), is not useful in the diagnosis of metabolic bone disease among patients with CKD, since it is cleared by the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Another resorption marker, tartrate-resistant acid phosphatase-5b (Trap-5b), which is not cleared by the kidney, has been associated with increased fractures in a cross-sectional study of CKD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/17\">",
"     17",
"    </a>",
"    ], but prospective studies are required to determine its utility in fracture prediction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic examination of bone can provide important information regarding the presence of hyperparathyroidism (such as subperiosteal resorption). However, radiographic findings are less sensitive than PTH levels and will not establish the type of bone disease. As a result, we no longer perform routine radiographic screening for bone disease in patients with ESRD. We reserve this test for patients with symptomatic bone disease.",
"   </p>",
"   <p>",
"    The 2006 NKF position paper on bone disease in CKD suggests the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone strength and quality &mdash; Minimal information is provided by plain radiographs in the vast majority of patients. Among those with severe disease, however, plain films may reveal subperiosteal resorption in patients with severe osteitis fibrosa or Looser zones in those with severe osteomalacia.",
"     </li>",
"     <li>",
"      Bone mineral density &mdash; The value of bone mineral density (BMD) measurement is unclear in patients with CKD. BMD as assessed at the distal radius site may predict fracture risk and correlate with PTH levels in dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. As result, the distal radius site is the preferred measurement site for BMD via DXA in patients with CKD. By comparison, BMD measurement at the hip or spine may be misleading, resulting in the inappropriate administration of anti-osteoporotic therapy. Even with the use of different anatomical sites, DXA does not provide an accurate assessment of fracture risk in CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/23\">",
"       23",
"      </a>",
"      ]. The 2012 KDIGO guidelines suggested not performing BMD measurements among patients with eGFR&lt;45",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2 since information may be misleading or unhelpful [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      To distinguish cortical from trabecular bone, BMD measurement by quantitative CT may help distinguish between underlying bone abnormalities in CKD. Hyperparathyroidism may result in sclerotic thickening of trabecular bone with increased BMD, while resorption is stimulated in cortical bone with reduced BMD; by comparison, reductions in trabecular BMD are observed in low turnover bone disease.",
"      <br/>",
"      <br/>",
"      DXA does not discriminate fracture status in patients with ESRD, as it does in postmenopausal and age-related osteoporosis. There is a need to develop non-invasive high-resolution imaging techniques that can improve fracture risk prediction for patients with CKD.",
"     </li>",
"     <li>",
"      Extraskeletal calcification &mdash; Detection of vascular calcification in adults may be done with a lateral abdominal radiography. This may reveal visible aortic calcification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Deferoxamine challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    (DFO) challenge test has been promoted as a means to detect or exclude aluminum&ndash;related bone diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/25\">",
"     25",
"    </a>",
"    ]. In general, a low DFO challenge test in the setting of markedly elevated serum intact PTH levels makes aluminum&ndash;related bone disease highly unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bone biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone biopsy is the gold standard for establishing the type of renal bone disease, since no combination of biochemical parameters is sufficiently accurate. This was shown in a retrospective study that compared serum intact PTH levels with results from bone biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/4\">",
"     4",
"    </a>",
"    ]. Bone biopsy was performed for different clinical syndromes, including severe bone pain, extraosseous calcifications, spontaneous fractures, hypercalcemia, excessive PTH levels, or possible aluminum accumulation. As determined by bone biopsy, approximately 40 percent of patients had osteitis fibrosa cystica, while 60 percent had different forms of low-turnover bone disease. No correlation was observed among bone biopsy results and PTH levels between 150 to 500",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    and 500 to 1,200",
"    <span class=\"nowrap\">",
"     pg/mL;",
"    </span>",
"    by comparison, there was a significant correlation between adynamic bone disease and PTH levels less than 150",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    These",
"    findings contrast with earlier studies showing a relationship between PTH and bone turnover. The discrepancies may be due to non-steady state conditions, since it takes about three months to achieve steady state rates of bone remodeling after changes in PTH. Alternatively, factors other than PTH may be regulating bone remodeling in CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controversy exists over the exact indications for bone biopsy. The major reason to obtain a bone biopsy is to diagnose the type of metabolic bone disease to provide treatments above and beyond routine care to prevent fractures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic bone disease. Both high and low bone turnover states in ESRD are associated with increased fracture risks. Since most patients are treated with active vitamin D analogues to prevent progressive increments in PTH (the main stimulus for high turnover), and since aluminum toxicity is now rare, there are few circumstances in which precise knowledge of the bone turnover and mineralization rate guides therapy.",
"   </p>",
"   <p>",
"    In general, most physicians would perform a bone biopsy to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establish the diagnosis of",
"      <span class=\"nowrap\">",
"       aplastic/adynamic",
"      </span>",
"      bone disease in symptomatic patients with serum PTH levels below 100",
"      <span class=\"nowrap\">",
"       pg/mL.",
"      </span>",
"     </li>",
"     <li>",
"      Determine the extent of bone aluminum accumulation prior to chelation therapy with DFO.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are differences in opinions regarding the use of bone biopsy to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct therapy in patients with intermediate serum PTH values between 100 and 450",
"      <span class=\"nowrap\">",
"       pg/mL.",
"      </span>",
"     </li>",
"     <li>",
"      Determine the extent of aluminum accumulation prior to parathyroidectomy, since low turnover bone disease with enhanced aluminum deposition may be precipitated if there is significant aluminum overload [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=see_link\">",
"       \"Indications for parathyroidectomy in end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history and laboratory evaluation may be helpful in the latter setting. In particular, significant aluminum accumulation is unlikely if there is no history of aluminum exposure and a low serum aluminum concentration with a negative DFO challenge test in the setting of intact PTH levels above 1000",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"    Thus, in this setting, we reserve bone biopsy for patients with lesser degrees of hyperparathyroidism who also have historical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biochemical evidence of aluminum accumulation. Synovial and bone biopsy is occasionally performed to establish the diagnosis of dialysis-related amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not routinely perform bone biopsies in subjects with modest elevations in serum PTH levels unless they have persistent symptoms following an empiric trial of calcitriol therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Guidelines and position statements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for bone metabolism and disease in CKD were published in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/25\">",
"     25",
"    </a>",
"    ]. Although these guidelines state that the performance of a bone biopsy is not necessary for most settings, it can be considered in patients with ESRD and the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fractures with minimal or no trauma",
"     </li>",
"     <li>",
"      Intact plasma PTH levels between 100 and 500",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      in association with unexplained hypercalcemia, severe bone pain, or unexplained increases in bone alkaline phosphatase activity",
"     </li>",
"     <li>",
"      Suspected aluminum bone disease, which is based upon clinical symptoms or history of aluminum exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2006, the National Kidney Foundation published a position statement in which bone biopsy was not recommended for routine evaluation of possible bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/5\">",
"     5",
"    </a>",
"    ]. The clinical indications for bone biopsy in patients with chronic kidney disease include but are not limited to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inconsistencies among biochemical parameters, thereby preventing definitive interpretation",
"     </li>",
"     <li>",
"      Unexplained skeletal fracture or bone pain",
"     </li>",
"     <li>",
"      Severe progressive vascular calcification",
"     </li>",
"     <li>",
"      Suspicion of overload or toxicity from aluminum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other metals",
"     </li>",
"     <li>",
"      Prior to parathyroidectomy if there was a clinical history of aluminum exposure or if the biochemical determinations are inconsistent with advanced secondary or tertiary hyperparathyroidism",
"     </li>",
"     <li>",
"      Consideration prior to beginning treatment with bisphosphonates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar recommendations were published in 2009 by the Kidney Disease Improving Global Outcomes Guidelines (KDIGO) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/29\">",
"     29",
"    </a>",
"    ]. A bone biopsy is reasonable in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unexplained fractures, unexplained hypercalcemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unexplained hypophosphatemia",
"     </li>",
"     <li>",
"      Persistent bone pain",
"     </li>",
"     <li>",
"      Possible aluminum toxicity",
"     </li>",
"     <li>",
"      Before therapy with bisphosphonates",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Technique of bone biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone biopsy is typically obtained from the iliac crest after the administration of time-spaced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    markers to determine the rate of new bone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28343/abstract/30\">",
"     30",
"    </a>",
"    ]. Our preferred approach is to obtain a transcortical sample with an 8 mm trocar. A typical labeling schedule requires two three-day periods of tetracycline labeling, separated by 21 days and preferably using two different types of tetracycline. The second labeling period must be completed two days before the biopsy. As an example, we typically administer tetracycline HCl, 250 mg TID, on days 23 to 25 before biopsy, followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"     demeclocycline",
"    </a>",
"    , 300 mg TID, on days two to four before biopsy. The bone specimen should be stained for aluminum and iron and read only by an experienced pathologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five major types of bone disease, collectively called renal osteodystrophy, occur in patients with advanced chronic renal failure. These include hyperparathyroid-mediated high-turnover bone disease or osteitis fibrosa; low turnover osteomalacia; mixed uremic osteodystrophy; osteomalacia; and adynamic bone. Each form of renal bone disease is associated with characteristic histologic findings. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tests that may be of some use in the evaluation of patients with possible renal osteodystrophy include the serum calcium, phosphorous, PTH and alkaline phosphatase (total or bone specific) levels, imaging studies, the desferoxamine challenge test, and bone biopsy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Circulating intact PTH levels predict the presence and severity of hyperparathyroidism but not necessarily the presence of underlying bone disease, particularly when PTH levels are only moderately elevated. Newer assays that detect the biologically active PTH 1-84 may offer enhanced standardization but little additional information from that provided from the traditional intact assay. If used, the second generation assays appear to provide values that are approximately 50 to 60 percent of those achieved with the intact assays. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Serum intact PTH concentration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=see_link\">",
"       \"Parathyroid hormone assays and their clinical use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone-specific or total alkaline phosphatase may provide useful information in conjunction with PTH measurements. Some experts feel that total serum alkaline phosphatase plus PTH levels are adequate in assessing bone formation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Alkaline phosphatase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic examination of bone may provide important information regarding the presence of hyperparathyroidism but are less sensitive than PTH levels and will not establish the type of bone disease. The distal radius site is the preferred measurement site for bone mineral density (BMD) measurement since it may predict fracture risk and correlates with PTH levels in dialysis patients. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone biopsy is the",
"      <strong>",
"       gold standard",
"      </strong>",
"      for establishing the type of renal bone disease. A bone biopsy may be considered in the setting of unexplained fractures, unexplained hypercalcemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unexplained hypophosphatemia; persistent bone pain; possible aluminum toxicity; and before therapy with bisphosphonates. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Bone biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/1\">",
"      Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990; 38:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/2\">",
"      Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure--an evolving disorder. Kidney Int 1993; 43:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/3\">",
"      Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/4\">",
"      Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005; 63:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/5\">",
"      Moe S, Dr&uuml;eke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/6\">",
"      Atsumi K, Kushida K, Yamazaki K, et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/7\">",
"      Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/8\">",
"      Sanchez CP, Salusky IB, Kuizon BD, et al. Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 1998; 53:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/9\">",
"      Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/10\">",
"      Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: the role of \"suppressed\" parathyroid function. Kidney Int 1993; 44:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/11\">",
"      Carmen S&aacute;nchez M, Auxiliadora Bajo M, Selgas R, et al. Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 2000; 36:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/12\">",
"      Moe SM. Management of renal osteodystrophy in peritoneal dialysis patients. Perit Dial Int 2004; 24:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/13\">",
"      Sprague SM. The role of the bone biopsy in the diagnosis of renal osteodystrophy. Semin Dial 2000; 13:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/14\">",
"      Ure&ntilde;a P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/15\">",
"      Ure&ntilde;a P, Hruby M, Ferreira A, et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/16\">",
"      Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 2009; 20:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/17\">",
"      Nickolas TL, Cremers S, Zhang A, et al. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 2011; 22:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/18\">",
"      Bauer D, Krege J, Lane N, et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 2012; 23:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/19\">",
"      Vasikaran S, Eastell R, Bruy&egrave;re O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/20\">",
"      Yamaguchi T, Kanno E, Tsubota J, et al. Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 1996; 19:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/21\">",
"      Ure&ntilde;a P, Bernard-Poenaru O, Ostertag A, et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003; 18:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/22\">",
"      Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 2007; 49:674.",
"     </a>",
"    </li>",
"    <li>",
"     Nickolas, TL, Leonard, MB, Shane, E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int 2008 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/24\">",
"      KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/25\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/26\">",
"      Mazzaferro S, Coen G, Ballanti P, et al. Deferoxamine test and PTH serum levels are useful not to recognize but to exclude aluminum-related bone disease. Nephron 1992; 61:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/27\">",
"      Slatopolsky E. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int 1987; 31:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/28\">",
"      Andress DL, Ott SM, Maloney NA, Sherrard DJ. Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 1985; 312:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/29\">",
"      KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28343/abstract/30\">",
"      Hodgson SF. Skeletal remodeling and renal osteodystrophy. Semin Nephrol 1986; 6:42.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7239 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28343=[""].join("\n");
var outline_f27_43_28343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Severe osteitis fibrosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mixed uremic osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Low turnover osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adynamic bone disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Aluminum deposition in bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TMV classification system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum intact PTH concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Alkaline phosphatase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1147942744\">",
"      Biochemical markers of bone resorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Deferoxamine challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bone biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Guidelines and position statements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Technique of bone biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7239|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/13/28883\" title=\"picture 1\">",
"      Normal bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/5/31832\" title=\"picture 2\">",
"      Osteitis fibrosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/57/20376\" title=\"picture 3\">",
"      Mixed osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/32/520\" title=\"picture 4\">",
"      Low turnover osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/56/31623\" title=\"picture 5\">",
"      Adynamic bone disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/21/4434\" title=\"picture 6\">",
"      Aluminum in bone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=related_link\">",
"      Indications for parathyroidectomy in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=related_link\">",
"      Parathyroid hormone assays and their clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_43_28344="Pathophysiology of gouty arthritis";
var content_f27_43_28344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of gouty arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28344/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28344/contributors\">",
"     Paul Monach, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28344/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28344/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28344/contributors\">",
"     H Ralph Schumacher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28344/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28344/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/43/28344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gout refers to disease that occurs in response to the presence of crystals of monosodium urate (MSU) in joints, bones, and soft tissues. Both acute arthritis and chronic arthropathy (tophaceous gout) are considered under the rubric of gout.",
"   </p>",
"   <p>",
"    The mechanisms of crystal deposition, crystal-induced inflammation, and destructive lesions of joints and bones associated with macroscopic collections of MSU (tophi) will be reviewed here. The clinical features, diagnosis, and treatment of acute gout; the prevention of recurrent gout; asymptomatic hyperuricemia; and associated renal diseases are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=see_link\">",
"     \"Treatment of acute gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"     \"Prevention of recurrent gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYPERURICEMIA AND GOUT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperuricemia can be caused by impaired renal excretion or overproduction of uric acid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by overconsumption of purine-rich foods that are metabolized to urate. Detailed discussions of the causes of hyperuricemia and of the normal mechanisms of urate handling are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24230?source=see_link\">",
"     \"Uric acid balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A causative relationship among hyperuricemia, deposition of urate crystals, and gout was proposed by Garrod in 1859 and later [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/1\">",
"     1",
"    </a>",
"    ]. However, injection of solutions of uric acid into blood or joints failed to reproduce the clinical features of the disease, casting doubt on the association. Freudweiler noted in 1899 that injection of tophaceous material caused inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The identification of MSU crystals within phagocytes when synovial fluid was examined using compensated polarized microscopy was an important advance in understanding the pathogenesis of gout [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/4\">",
"     4",
"    </a>",
"    ]. This was followed by the observation that injection of MSU crystals into normal joints produced acute gout attacks, reestablishing the connection between urate crystals and gout [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The outline of the pathophysiology of gout is as follows: a period of hyperuricemia leads to MSU crystal deposition, reaction to which can result in acute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic inflammation.",
"   </p>",
"   <p>",
"    Risk factors that have been associated with the development of gout appear to mediate their effects, at least in part, through increased extracellular urate levels, reflected by hyperuricemia. Non-modifiable risk factors include male gender, advanced age, and ethnicity (eg, Pacific Islanders). Modifiable risk factors include obesity; diets rich in meat and seafood content; alcohol-containing beverages (especially beer and distilled spirits); sodas and fruit juices high in fructose content; hypertension; thiazide or loop diuretic use; postmenopausal and organ transplant recipient status; use of certain medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A or low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , although cardioprotective aspirin doses of only 81 to 325",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    generally do not increase attack frequency to a significant degree and do not warrant discontinuation); and toxic exposures (eg, lead).",
"   </p>",
"   <p>",
"    Lead toxicity has been associated with gout since the 1700s, but the mechanism has been a matter of debate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/7\">",
"     7",
"    </a>",
"    ]. Some evidence has suggested that blood lead levels widely considered to be within an acceptable range may be associated with an increased prevalence of gout [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/8\">",
"     8",
"    </a>",
"    ]; in population-based data from the National Health and Nutrition Examination Survey (NHANES) for 2005 to 2008 in the United States, individuals in the highest blood lead level quartile (mean of 0.19",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [3.95",
"    <span class=\"nowrap\">",
"     mcg/dL])",
"    </span>",
"    had a significantly higher risk for gout and for hyperuricemia compared with those in the lowest quartile for blood lead levels (mean of 0.04",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [0.89",
"    <span class=\"nowrap\">",
"     mcg/dL])",
"    </span>",
"    (odds ratios for gout of 3.6, 95% CI 2.1-6.3, and for hyperuricemia of 1.9, 95% CI 1.3-2.6). These findings need confirmation, and it is unknown whether interventions to lower such levels will reduce risk.",
"   </p>",
"   <p>",
"    All genetic mutations or polymorphisms associated with gout are also associated with hyperuricemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/9\">",
"     9",
"    </a>",
"    ]. However, although hyperuricemia is a necessary predisposing factor, its presence does not always lead to the development of gout. Indeed, the majority of hyperuricemic patients never develop gout [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Individual differences in the formation of crystals or in inflammatory responses to those crystals (or both) may play a role in determining whether a person with hyperuricemia will develop gout. Favoring an unexplained increase in crystal formation in those with gout is the observation that crystals are frequently found in synovial fluid from uninflamed joints [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/13\">",
"     13",
"    </a>",
"    ], but it is unusual to find them in joint fluid from non-gouty hyperuricemic people [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/14\">",
"     14",
"    </a>",
"    ]. Higher levels of uric acid in the blood clearly bring a greater risk for developing gout [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], although not necessarily more severe gout. Obesity and ethanol ingestion further increase the risk for gout at any given level of hyperuricemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/15\">",
"     15",
"    </a>",
"    ]. Among people with an established history of gout, consumption of alcohol or intermittent use of diuretics, which may result in abrupt changes in extracellular fluid urate levels, appear to acutely increase the risk of an attack [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, there have not been completely satisfactory explanations for some of the fascinating clinical aspects of acute gout, including [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Precipitation of acute attacks by trauma or surgery",
"     </li>",
"     <li>",
"      Predilection for the first metatarsal-phalangeal (MTP) joint",
"     </li>",
"     <li>",
"      Spontaneous resolution of attacks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plausible though unproven explanations for the frequent involvement of the first MTP include relative coolness of the feet (reducing the solubility of MSU); the repeated microtrauma to which the MTP joint is subjected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/22\">",
"     22",
"    </a>",
"    ]; and differential reabsorption into the joint of exuded solvent (joint fluid) and solute (urate) from the periarticular area when weightbearing is replaced by recumbency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the initiation of antihyperuricemic therapy, although protective in the long term, can initially precipitate acute gouty arthritis. Prophylaxis is usually given to prevent this complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link&amp;anchor=H24#H24\">",
"     \"Prevention of recurrent gout\", section on 'Prophylaxis during initiation of antihyperuricemic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CRYSTALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The solubility of MSU in physiologic saline at 37&ordm;C, about 7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (416",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    is approximately the same concentration above which patients are at risk of developing gout [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Measurements of MSU solubility in plasma and serum have varied more widely than those in saline, although the average value is similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;The solubility of MSU falls rapidly with decreasing temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/24\">",
"     24",
"    </a>",
"    ]. Noninflamed synovial fluid is significantly cooler than serum, being 90 to 91&ordm;F (32&ordm;C) in the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/25\">",
"     25",
"    </a>",
"    ], so the key value for urate solubility in a tissue of a given joint could be considerably less than 7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (416",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nucleation and growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solubility",
"    is a thermodynamic parameter determined when a fluid is in equilibrium with a solid phase. Supersaturation may persist if nucleation and growth of MSU crystals do not occur. Indeed, MSU has been noted to remain in solution indefinitely at a concentration of 84",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/26\">",
"     26",
"    </a>",
"    ]. Data are conflicting on whether particular components of cartilage or joint fluid promote or inhibit the critical nucleation step [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/27\">",
"     27",
"    </a>",
"    ]. Amid this uncertainty, immunoglobulin (Ig) stands out as a likely promoter of nucleation, although whether by nonspecific or by MSU-specific binding is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. MSU crystals from tophi and synovial fluid during acute gout are coated with Ig [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both nucleation rates and subsequent growth rates of MSU crystals are directly proportional to the degree of MSU supersaturation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/32\">",
"     32",
"    </a>",
"    ]. Together, these data provide an explanation for, but not a detailed mechanism of, the observations that hyperuricemia is necessary but not sufficient for the development of gout and that risk increases with increasing concentration of uric acid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INFLAMMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phagocytosis of MSU crystals by neutrophils plays a central role in an acute attack of gout. In an experimental animal model, depletion of neutrophils with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    prior to injection of MSU crystals prevented inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/33\">",
"     33",
"    </a>",
"    ]. Such treatment could also affect other cell types. Synovial cells, monocytes, and endothelial cells have all been shown to phagocytose MSU and to release various mediators of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Phagocytosis of MSU crystals by synovial lining cells (some of which are macrophage-like) precedes influx of neutrophils in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macrophage phagocytosis of MSU crystals and subsequent cytokine release may require the presence of cell surface receptors of the innate immune system. In some murine model systems, the absence of the toll-like receptors, TLR-2 or TLR-4; of the TLR adapter protein; of myeloid differentiation factor 88 (MyD88); or of an adapter protein shared by TLR-2 and TLR-4 (CD14) is associated with blunted production of proinflammatory cytokines in vitro and in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, in another murine model, although MyD88 signaling was critically important, toll-like receptors did not appear to play a role in the inflammatory response to intraperitoneally injected MSU crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monocytes and synoviocytes release interleukin&ndash;1 (IL-1), IL-6, IL-8, and tumor necrosis factor (TNF) in response to MSU crystals in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/35,42-44\">",
"     35,42-44",
"    </a>",
"    ]. Increased levels of IL-6, IL-8, and TNF occur in gouty tissues in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Blockade of IL-8 or of TNF activity prevents MSU-induced inflammation in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The ability of crystals of MSU to cause increased production of cytokines and chemokines involves effects on gene transcription and stabilization of mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MSU crystal-induced release of IL-1, IL-6, and TNF from the monocytes of patients with end-stage renal disease (ESRD) is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/48\">",
"     48",
"    </a>",
"    ]. The decrease in production of selected cytokines is present whether or not such patients are on hemodialysis. This phenomenon may partially explain the observation that patients with ESRD develop gout relatively infrequently despite the presence of severe hyperuricemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/48\">",
"     48",
"    </a>",
"    ]. However, it is unknown if either azotemia or dialytic therapy affects MSU crystal nucleation or growth.",
"   </p>",
"   <p>",
"    Recruitment and activation of neutrophils appears to be dependent upon locally produced cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Interleukin 1 is probably an important factor; rodents deficient in IL-1 receptors do not mount as vigorous an inflammatory response as wild-type animals do to injected MSU crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/41,51\">",
"     41,51",
"    </a>",
"    ], and clinical trials of IL-1 antagonists support a central role for IL-1 in human gout [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears that resident tissue cells rather than bone marrow-derived cells utilize the IL-1 signaling pathway, as irradiated chimeric animals transplanted with bone marrow cells lacking IL-1 receptors are able to mount a neutrophil response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/41\">",
"     41",
"    </a>",
"    ]. Crystals of MSU activate the particular inflammasome that contains cryopyrin (also referred to as the NALP3 or PYPAF1 protein), thereby generating IL-1 beta [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/54\">",
"     54",
"    </a>",
"    ]. Neutrophils respond to MSU crystals with a respiratory burst and release of lysosomal enzymes, superoxide anion, leukotriene B4, and IL-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/49,55-59\">",
"     49,55-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cellular biology and intracellular signaling mechanisms involved in neutrophil chemotaxis and activation in response to crystals have been intensively investigated and are quite complex [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Tyrosine kinases, phospholipases, chemoattractants, and adhesion molecules such as E-selectin may all play important roles in gout and are potential targets for therapeutic interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/62-65\">",
"     62-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    , long used for the treatment and prophylaxis of gout, inhibits tyrosine phosphorylation in neutrophils in response to crystals (MSU or calcium pyrophosphate) but does not inhibit this pathway when bacterial products are the stimulus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/62\">",
"     62",
"    </a>",
"    ]. Colchicine blocks activation of the NALP3 inflammasome in monocytes by MSU crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/54\">",
"     54",
"    </a>",
"    ]. At low doses, colchicine interferes with microtubule function and inhibits the activity of relevant adhesion molecules on neutrophils and on endothelial cells; these effects may inhibit neutrophil migration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proteins attached to MSU crystals have important modulating effects on the inflammatory response. Depending upon the type of protein, the result may be proinflammatory or antiinflammatory. As an example of proinflammatory effects, MSU crystals derived from tophi produce more inflammation than synthetic ones, a difference that is eliminated by protease treatment of tophi [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/68\">",
"     68",
"    </a>",
"    ]. Binding of IgG to MSU crystals results in an increased release of superoxide and lysosomal enzymes from human neutrophils in vitro when compared with protein-free crystal-induced release of these substances [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/58,69,70\">",
"     58,69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inflammatory potential of MSU crystals is reduced when lipoproteins, particularly those containing apolipoprotein B (ApoB), are allowed to bind to them before injection in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/71\">",
"     71",
"    </a>",
"    ]. Effects of these lipoproteins are likely to play a role in the self-limited nature of acute gout. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Spontaneous resolution'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The role of the kinin and complement systems in acute gout is unclear. MSU crystals can activate Hageman factor, and kinins can be detected in inflamed joints. However, acute inflammation still occurs in experimental models where these mediators are absent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. MSU crystals can activate complement by both the classical and alternative pathways and by a mechanism dependent upon the presence of either IgG or C-reactive protein [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. However, depletion or deficiency of complement results in incomplete inhibition of inflammation in experimental models [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Total hemolytic complement is elevated, rather than depleted, in synovial fluid during acute inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/79\">",
"     79",
"    </a>",
"    ]. The dispensability of the kinin and complement systems in gouty attacks does not mean that they do not participate at all. Antiinflammatory synergy did not occur with blockade of both systems, but an additive effect was present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SPONTANEOUS RESOLUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even without treatment, a typical attack of acute gout resolves within a few weeks. There are many feedback mechanisms that tend to limit inflammatory states, such as the inactivation of inflammatory mediators; death, deactivation, or differentiation of inflammatory cells; and upregulation of antiinflammatory mediators, such as transforming growth factor-beta (TGF-beta), IL-1 receptor antagonist (IL-1ra), and peroxisome proliferator-activated receptor gamma (PPAR gamma) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. These are likely to play a role in limiting the duration of an acute attack of gout [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The different responses to MSU crystals of cells of the monocyte-macrophage lineage obtained from sites of early and late inflammation are illustrative. Leukocytes, when recovered 16 hours after an experimentally-induced blistering skin lesion, predominantly secrete proinflammatory cytokines (eg, TNF) when exposed to MSU in vitro; leukocytes recovered from blister fluid at 40 hours after injury produce the antiinflammatory cytokine TGF-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dissolution of urate crystals by products of phagocytes, including superoxide, could also serve to turn off inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/83\">",
"     83",
"    </a>",
"    ]. However, resolution of an acute attack of gout occurs even in the ongoing presence of crystals. The physical properties of crystals may change with inflammation. Indeed, neutrophil products remove IgG from MSU crystals thereby making them less inflammatory [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/84\">",
"     84",
"    </a>",
"    ]. Perhaps more importantly, increasing amounts of antiinflammatory ApoB bind to MSU crystals during the course of an attack [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     THE TOPHUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tophi are deposits of MSU crystals surrounded by granulomatous inflammation. They are most often found in joints, bone, cartilage, and skin but may (uncommonly) be found in parenchymal organs as well. The tissue reaction to a tophus is generally chronic inflammatory in type; both innate immunity and adaptive immunity participate. Although clinical signs of acute inflammation sometimes occur in tophi, this is unusual; swelling accompanying a tophus is most often due to the mass of crystals itself.",
"   </p>",
"   <p>",
"    Surgically obtained tophi from 12 established gout patients were analyzed by quantitative immunohistochemistry [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/86\">",
"     86",
"    </a>",
"    ]. The coronal zones of the tophi (relative to the surrounding fibrovascular zones) contained substantial numbers of CD68+ mononuclear macrophages, multinucleated CD68+ cells (to a lesser extent), and plasma cells but contained very few neutrophils. CD20+ B cells, present in small numbers, were found in the fibrovascular zone, and both mast cells and T cells were found in modest numbers in both sites. Of note, IL-1 beta was frequently expressed by CD68+ cells in the corona, and the number of mononuclear cells expressing IL-1 beta correlated with number expressing antiinflammatory TGF-beta1.",
"   </p>",
"   <p>",
"    These findings indicate that the tophus is a complex but organized chronic inflammatory response to urate crystal deposition, in which both innate immunity and adaptive immunity participate. It seems likely that correlated expression of both pro- and antiinflammatory factors in these lesions is reflected by the cyclic processes of tophus inflammation and resolution and of tissue remodeling.",
"   </p>",
"   <p>",
"    Visible or palpable tophi are usually noted only among those patients who have had repeated attacks of acute gout, often over many years. However, microscopic examination of synovium from those with acute gout, but without macroscopic tophi, can show micro-tophi, which are surrounded by only a thin rim of fibrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/87\">",
"     87",
"    </a>",
"    ]. Although unsubstantiated, the initiation of an acute gout attack may begin with the release of MSU crystals from micro-tophi into the synovial fluid or may actually begin in the tissue. The latter mechanism is consistent with the clinical observation that joint fluid obtained shortly after the onset of symptoms is sometimes free of crystals, while a repeat aspiration a day or more later is floridly positive [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/88\">",
"     88",
"    </a>",
"    ]. It is particularly tempting to ascribe post-traumatic acute gout to this mechanism.",
"   </p>",
"   <p>",
"    Crystals of MSU from tophi are associated with IgG and other proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/30\">",
"     30",
"    </a>",
"    ]. Their biology is probably complex, as evidenced by conflicting data on their inflammatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28344/abstract/68,89\">",
"     68,89",
"    </a>",
"    ]. The pathologic effects of tophi, particularly their ability to cause erosion of bone, cartilage, and soft tissues, are poorly understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244423514\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperuricemia can be caused by impaired renal excretion or overproduction of uric acid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      by overconsumption of purine-rich foods that are metabolized to urate. In some hyperuricemic individuals, a period of hyperuricemia leads to monosodium urate (MSU) crystal deposition, reaction to which can result in the acute",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic inflammation associated with the signs and symptoms of gout. Hyperuricemia is a necessary predisposing factor, although the majority of hyperuricemic patients never develop gout. Individual differences in the formation of crystals",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in inflammatory responses to those crystals may play a role in whether a person with hyperuricemia will develop gout. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hyperuricemia and gout'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors associated with the development of gout include non-modifiable risk factors, such as male gender, advanced age, and ethnicity, and modifiable risk factors, such as obesity; diets rich in meat and seafood content; alcohol-containing beverages (especially beer and distilled spirits); sodas and fruit juices high in fructose content; hypertension; thiazide or loop diuretic use; postmenopausal and organ transplant recipient status; use of certain medications (low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      A); and toxic exposure (eg, lead). Obesity and ethanol ingestion further increase the risk for gout at any given level of hyperuricemia. Among persons with an established history of gout, consumption of alcohol or intermittent use of diuretics, which may result in abrupt changes in extracellular fluid urate levels, appear to acutely increase the risk of an attack. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hyperuricemia and gout'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The solubility of MSU in physiologic saline at 37&ordm;C, about 7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (416",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      is approximately the same concentration above which patients are at risk of developing gout. The solubility of MSU falls rapidly with decreasing temperature. It is unclear whether particular components of cartilage and joint fluid promote or inhibit crystal nucleation, but immunoglobulin is a likely promoter. Both nucleation rates and subsequent growth rates of MSU crystals are directly proportional to the degree of MSU supersaturation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Crystals'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Temperature'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Nucleation and growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The phagocytosis of MSU crystals by neutrophils plays a central role in an acute attack of gout. Such phagocytosis may require the presence of cell surface receptors of the innate immune system. Neutrophils respond to MSU crystals with a respiratory burst and release of lysosomal enzymes, superoxide anion, leukotriene B4, and IL-1. The cellular biology and intracellular signaling mechanisms involved in neutrophil chemotaxis and activation in response to crystals are complex, involving kinases, phospholipases, chemoattractants, adhesion molecules, and other factors. Synovial cells, monocytes, and endothelial cells have all been shown to phagocytose MSU and to release various mediators of inflammation, including interleukin&ndash;1 (IL-1), IL-6, IL-8, and tumor necrosis factor (TNF). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Inflammation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Even without treatment, a typical attack of acute gout resolves within a few weeks. There are many feedback mechanisms that tend to limit inflammatory states and that are likely to play a role in limiting the duration of an acute attack of gout. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Spontaneous resolution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tophi are deposits of MSU crystals surrounded by granulomatous inflammation. They are most often found in joints, bone, cartilage, and skin but may (uncommonly) be found in parenchymal organs as well. The tissue reaction to a tophus is generally chronic inflammatory in type; both innate immunity and adaptive immunity participate. Although clinical signs of acute inflammation sometimes occur in tophi, this is unusual; swelling accompanying a tophus is most often due to the mass of crystals itself. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'The tophus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Garrod AB. The Nature and Treatment of Gout and Rheumatic Gout, 2nd Edition, 1863.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/2\">",
"      BRILL JM, MCCARTY DJ. \"STUDIES ON THE NATURE OF GOUTY TOPHI\" BY MAX FREUDWEILER, 1899. (AN INFLAMMATORY RESPONSE TO INJECTED SODIUM URATE, 1899). AN ABRIDGED TRANSLATION, WITH COMMENTS. Ann Intern Med 1964; 60:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/3\">",
"      FREUDWEILER M. EXPERIMENTAL INVESTIGATIONS INTO THE ORIGIN OF GOUTY TOPHI. Arthritis Rheum 1965; 8:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/4\">",
"      MCCARTY DJ, HOLLANDER JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/5\">",
"      Seegmiller JE, Howell RR, Malawista SE. The inflammatory reaction to sodium urate: its possible relationship to the genesis of acute gouty arthritis. JAMA 1962; 180:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/6\">",
"      Faires JS, McCarty DJ. Acute arthritis in man and dog after intrasynovial injection of sodium urate crystals. Lancet 1962; 2:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/7\">",
"      Reynolds PP, Knapp MJ, Baraf HS, Holmes EW. Moonshine and lead. Relationship to the pathogenesis of hyperuricemia in gout. Arthritis Rheum 1983; 26:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/8\">",
"      Krishnan E, Lingala B, Bhalla V. Low-level lead exposure and the prevalence of gout: an observational study. Ann Intern Med 2012; 157:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/9\">",
"      Riches PL, Wright AF, Ralston SH. Recent insights into the pathogenesis of hyperuricaemia and gout. Hum Mol Genet 2009; 18:R177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/10\">",
"      Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 1967; 42:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/11\">",
"      Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/12\">",
"      Zalokar J, Lellouch J, Claude JR, Kuntz D. Epidemiology of serum uric acid and gout in Frenchmen. J Chronic Dis 1974; 27:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/13\">",
"      Agudelo CA, Weinberger A, Schumacher HR, et al. Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints. Arthritis Rheum 1979; 22:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/14\">",
"      Rouault T, Caldwell DS, Holmes EW. Aspiration of the asymptomatic metatarsophalangeal joint in gout patients and hyperuricemic controls. Arthritis Rheum 1982; 25:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/15\">",
"      Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000; 27:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/16\">",
"      Zhang Y, Woods R, Chaisson CE, et al. Alcohol consumption as a trigger of recurrent gout attacks. Am J Med 2006; 119:800.e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/17\">",
"      Hunter DJ, York M, Chaisson CE, et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006; 33:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/18\">",
"      Craig MH, Poole GV, Hauser CJ. Postsurgical gout. Am Surg 1995; 61:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/19\">",
"      Chakravarty K, Durkin CJ, al-Hillawi AH, et al. The incidence of acute arthritis in stroke patients, and its impact on rehabilitation. Q J Med 1993; 86:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/20\">",
"      Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/21\">",
"      Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51:321.",
"     </a>",
"    </li>",
"    <li>",
"     Terkeltaub R. Gout. A. Epidemiology, pathology, and pathogenesis. In: Primer on the Rheumatic Diseases, 12th Edition, Klippel JH (Ed), Arthritis Foundation, Atlanta 2001. p.307.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/23\">",
"      Simkin PA. The pathogenesis of podagra. Ann Intern Med 1977; 86:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/24\">",
"      Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972; 15:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/25\">",
"      HORVATH SM, HOLLANDER JL. Intra-articular temperature as a measure of joint reaction. J Clin Invest 1949; 28:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/26\">",
"      Tak HK, Cooper SM, Wilcox WR. Studies on the nucleation of monosodium urate at 37 degrees c. Arthritis Rheum 1980; 23:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/27\">",
"      McGill NW, Dieppe PA. The role of serum and synovial fluid components in the promotion of urate crystal formation. J Rheumatol 1991; 18:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/28\">",
"      Hasselbacher P. Binding of IgG and complement protein by monosodium urate monohydrate and other crystals. J Lab Clin Med 1979; 94:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/29\">",
"      Kam M, Perl-Treves D, Caspi D, Addadi L. Antibodies against crystals. FASEB J 1992; 6:2608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/30\">",
"      Hasselbacher P, Schumacher HR. Immunoglobulin in tophi and on the surface of monosodium urate crystals. Arthritis Rheum 1978; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/31\">",
"      Cherian PV, Schumacher HR Jr. Immunochemical and ultrastructural characterization of serum proteins associated with monosodium urate crystals (MSU) in synovial fluid cells from patients with gout. Ultrastruct Pathol 1986; 10:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/32\">",
"      Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis 1983; 42 Suppl 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/33\">",
"      Phelps P, McCarty DJ Jr. Crystal-induced inflammation in canine joints. II. Importance of polymorphonuclear leukocytes. J Exp Med 1966; 124:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/34\">",
"      Wigley FM, Fine IT, Newcombe DS. The role of the human synovial fibroblast in monosodium urate crystal-induced synovitis. J Rheumatol 1983; 10:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/35\">",
"      Malawista SE, Duff GW, Atkins E, et al. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum 1985; 28:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/36\">",
"      Falasca GF, Ramachandrula A, Kelley KA, et al. Superoxide anion production and phagocytosis of crystals by cultured endothelial cells. Arthritis Rheum 1993; 36:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/37\">",
"      Schumacher HR, Phelps P, Agudelo CA. Urate crystal induced inflammation in dog joints: sequence of synovial changes. J Rheumatol 1974; 1:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/38\">",
"      Gordon TP, Kowanko IC, James M, Roberts-Thomson PJ. Monosodium urate crystal-induced prostaglandin synthesis in the rat subcutaneous air pouch. Clin Exp Rheumatol 1985; 3:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/39\">",
"      Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005; 52:2936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/40\">",
"      Scott P, Ma H, Viriyakosol S, et al. Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 2006; 177:6370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/41\">",
"      Chen CJ, Shi Y, Hearn A, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006; 116:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/42\">",
"      Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989; 32:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/43\">",
"      Terkeltaub R, Zachariae C, Santoro D, et al. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991; 34:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/44\">",
"      di Giovine FS, Malawista SE, Thornton E, Duff GW. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest 1991; 87:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/45\">",
"      Terkeltaub R, Baird S, Sears P, et al. The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute urate crystal-induced gouty synovitis. Arthritis Rheum 1998; 41:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/46\">",
"      Chapman PT, Yarwood H, Harrison AA, et al. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1997; 40:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/47\">",
"      Jaramillo M, Godbout M, Naccache PH, Olivier M. Signaling events involved in macrophage chemokine expression in response to monosodium urate crystals. J Biol Chem 2004; 279:52797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/48\">",
"      Schreiner O, Wandel E, Himmelsbach F, et al. Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients? Nephrol Dial Transplant 2000; 15:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/49\">",
"      Roberge CJ, de M&eacute;dicis R, Dayer JM, et al. Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. J Immunol 1994; 152:5485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/50\">",
"      Burt HM, Jackson JK. The priming action of tumour necrosis factor-alpha (TNF-alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophils activated by inflammatory microcrystals. Clin Exp Immunol 1997; 108:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/51\">",
"      Torres R, Macdonald L, Croll SD, et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 2009; 68:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/52\">",
"      So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/53\">",
"      Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/54\">",
"      Martinon F, P&eacute;trilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/55\">",
"      Simchowitz L, Atkinson JP, Spilberg I. Stimulation of the respiratory burst in human neutrophils by crystal phagocytosis. Arthritis Rheum 1982; 25:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/56\">",
"      Hoffstein S, Weissmann G. Mechanisms of lysosomal enzyme release from leukocytes. IV. Interaction of monosodium urate crystals with dogfish and human leukocytes. Arthritis Rheum 1975; 18:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/57\">",
"      Lin HY, Rocher LL, McQuillan MA, et al. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989; 321:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/58\">",
"      Abramson S, Hoffstein ST, Weissmann G. Superoxide anion generation by human neutrophils exposed to monosodium urate. Arthritis Rheum 1982; 25:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/59\">",
"      Rae SA, Davidson EM, Smith MJ. Leukotriene B4, an inflammatory mediator in gout. Lancet 1982; 2:1122.",
"     </a>",
"    </li>",
"    <li>",
"     Terkeltaub R. Pathogenesis of inflammatory manifestations caused by crystals. In: Gout, Hyperuricemia, and Other Crystal-associated Arthropathies, Smyth CJ, Holers VM (Eds), Marcel Dekker, New York 1999. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/61\">",
"      Liu-Bryan R, Liot&eacute; F. Monosodium urate and calcium pyrophosphate dihydrate (CPPD) crystals, inflammation, and cellular signaling. Joint Bone Spine 2005; 72:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/62\">",
"      Gaudry M, Roberge CJ, de M&eacute;dicis R, et al. Crystal-induced neutrophil activation. III. Inflammatory microcrystals induce a distinct pattern of tyrosine phosphorylation in human neutrophils. J Clin Invest 1993; 91:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/63\">",
"      Jackon JK, Tudan C, Burt HM. The involvement of phospholipase C in crystal induced human neutrophil activation. J Rheumatol 2000; 27:2877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/64\">",
"      Ryckman C, McColl SR, Vandal K, et al. Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum 2003; 48:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/65\">",
"      Chapman PT, Jamar F, Harrison AA, et al. Noninvasive imaging of E-selectin expression by activated endothelium in urate crystal-induced arthritis. Arthritis Rheum 1994; 37:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/66\">",
"      Zhou X, Li J, Kucik DF. The microtubule cytoskeleton participates in control of beta2 integrin avidity. J Biol Chem 2001; 276:44762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/67\">",
"      Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/68\">",
"      Stankov&iacute;c A, Front P, Barbara A, Mitrov&iacute;c DR. Tophus-derived monosodium urate monohydrate crystals are biologically much more active than synthetic counterpart. Rheumatol Int 1991; 10:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/69\">",
"      Nagase M, Baker DG, Schumacher HR Jr. Immunoglobulin G coating on crystals and ceramics enhances polymorphonuclear cell superoxide production: correlation with immunoglobulin G adsorbed. J Rheumatol 1989; 16:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/70\">",
"      Kozin F, Ginsberg MH, Skosey JL. Polymorphonuclear leukocyte responses to monosodium urate crystals: modification by adsorbed serum proteins. J Rheumatol 1979; 6:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/71\">",
"      Terkeltaub R, Curtiss LK, Tenner AJ, Ginsberg MH. Lipoproteins containing apoprotein B are a major regulator of neutrophil responses to monosodium urate crystals. J Clin Invest 1984; 73:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/72\">",
"      Phelps P, Prockop DJ, McCarty DJ. Crystal induced inflammation in canine joints. 3. Evidence against bradykinin as a mediator of inflammation. J Lab Clin Med 1966; 68:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/73\">",
"      Spilberg I. Urate crystal arthritis in animals lacking Hageman factor. Arthritis Rheum 1974; 17:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/74\">",
"      Fields TR, Abramson SB, Weissmann G, et al. Activation of the alternative pathway of complement by monosodium urate crystals. Clin Immunol Immunopathol 1983; 26:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/75\">",
"      Russell IJ, Papaioannou C, McDuffie FC, et al. Effect of IgG and C-reactive protein on complement depletion by monosodium urate crystals. J Rheumatol 1983; 10:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/76\">",
"      Webster ME, Maling HM, Zweig MH, et al. Urate crystal induced inflammation in the rat: evidence for the combined actions of kinins, histamine and components of complement. Immunol Commun 1972; 1:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/77\">",
"      Kellermeyer RW, Naff GB. Chemical mediators of inflammation in acute gouty arthritis. Arthritis Rheum 1975; 18:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/78\">",
"      Tramontini N, Huber C, Liu-Bryan R, et al. Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum 2004; 50:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/79\">",
"      Townes AS, Sowa JM. Complement in synovial fluid. Johns Hopkins Med J 1970; 127:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/80\">",
"      Yagnik DR, Evans BJ, Florey O, et al. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2004; 50:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/81\">",
"      Akahoshi T, Namai R, Murakami Y, et al. Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. Arthritis Rheum 2003; 48:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/82\">",
"      Terkeltaub RA. What stops a gouty attack? J Rheumatol 1992; 19:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/83\">",
"      Marcolongo R, Calabria AA, Lalumera M, et al. The \"switch-off\" mechanism of spontaneous resolution of acute gout attack. J Rheumatol 1988; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/84\">",
"      Rosen MS, Baker DG, Schumacher HR Jr, Cherian PV. Products of polymorphonuclear cell injury inhibit IgG enhancement of monosodium urate-induced superoxide production. Arthritis Rheum 1986; 29:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/85\">",
"      Ortiz-Bravo E, Sieck MS, Schumacher HR Jr. Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum 1993; 36:1274.",
"     </a>",
"    </li>",
"    <li>",
"     Dalbeth N, Pool B, Gamble G, et al. Cellular characterization of the gouty tophus: A quantitiative analysis. (abstract number 1947). Presented at the American College of Rheumatology Annual Scientific Sessions, October 20, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/87\">",
"      Agudelo CA, Schumacher HR. The synovitis of acute gouty arthritis. A light and electron microscopic study. Hum Pathol 1973; 4:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/88\">",
"      Schumacher HR, Jimenez SA, Gibson T, et al. Acute gouty arthritis without urate crystals identified on initial examination of synovial fluid. Arthritis Rheum 1975; 18:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28344/abstract/89\">",
"      Gordon TP, Roberts-Thomson PJ. Preliminary evidence for the presence of an inhibitor on the surface of natural monosodium urate crystals. Arthritis Rheum 1986; 29:1172.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1673 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28344=[""].join("\n");
var outline_f27_43_28344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H244423514\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYPERURICEMIA AND GOUT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CRYSTALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Temperature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nucleation and growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INFLAMMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SPONTANEOUS RESOLUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      THE TOPHUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H244423514\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=related_link\">",
"      Prevention of recurrent gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=related_link\">",
"      Treatment of acute gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24230?source=related_link\">",
"      Uric acid balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_43_28345="Chemotherapy for differentiated thyroid cancer";
var content_f27_43_28345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemotherapy for differentiated thyroid cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28345/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28345/contributors\">",
"     Steven I Sherman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28345/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28345/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28345/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/43/28345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of most patients with differentiated thyroid carcinoma (both papillary [PTC] and follicular [FTC] histologies) includes surgery, radioactive iodine, and thyroid hormone therapy. When metastatic disease occurs, radioactive iodine can be curative in a minority of patients, and TSH-suppressive thyroid hormone therapy can help to slow the pace of the disease. In addition, external radiotherapy may be useful in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"     \"Overview of the management of differentiated thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=see_link\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39191?source=see_link\">",
"     \"External beam radiotherapy in the treatment of thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, for those patients with metastatic differentiated thyroid carcinoma (DTC) that progresses despite radioiodine and TSH-suppressive thyroid hormone therapy, treatment options have historically been limited. New approaches, based upon application of targeted chemotherapies, are emerging as effective alternatives for progressive disease, although most remain investigational. Current and experimental chemotherapies for advanced differentiated thyroid carcinoma will be reviewed here. Chemotherapies for medullary and anaplastic thyroid carcinomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=see_link\">",
"     \"Chemotherapy and immunotherapy for medullary thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23721?source=see_link\">",
"     \"Anaplastic thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYROSINE KINASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most tumors, tyrosine kinases function as key signaling intermediates that stimulate tumor proliferation, angiogenesis, invasion, metastasis, and avoidance of apoptosis, affecting both the cancer cells as well as the other components of the tumor microenvironment, such as the vascular endothelium. Small molecule inhibitors targeting signaling tyrosine kinases have been of interest for the treatment of advanced differentiated thyroid cancer, given the oncogenic roles of mutations in the serine kinase BRAF, and tyrosine kinases RET (in the mutated fusion protein",
"    <span class=\"nowrap\">",
"     RET/PTC,",
"    </span>",
"    the",
"    <span class=\"nowrap\">",
"     &ldquo;RET/PTC",
"    </span>",
"    oncogene&rdquo;) and RAS, and the contributory roles of tyrosine kinases in growth factor receptors such as the vascular endothelial growth factor receptor (VEGFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=see_link\">",
"     \"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These drugs partially inhibit multiple tyrosine kinases (ie, they are multitargeted) at nanomolar concentrations in vitro, and often affect multiple signaling pathways.",
"   </p>",
"   <p>",
"    A wide variety of multitargeted kinase inhibitors have entered clinical trials for patients with advanced or progressing metastatic thyroid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/3\">",
"     3",
"    </a>",
"    ]. Given the considerable structural similarity between RET and VEGFR kinases, most of these small molecule inhibitors are capable of affecting both kinases. However, the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    to induce objective responses in the absence of significant anti-RET activity suggests that RET may not be as important a target for therapy as VEGFR. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pazopanib'",
"    </a>",
"    below.) Further, in the limited clinical trials that studied tumor genotyping,",
"    <span class=\"nowrap\">",
"     RET/PTC",
"    </span>",
"    mutations were uncommonly seen in patients being treated for advanced papillary thyroid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These drugs remain investigational for the treatment of refractory metastatic DTC. In preliminary trials (described below), partial responses are reported in approximately 15 to 30 percent of patients. Complete responses are absent, and no study has evaluated survival. Thus, for most patients with metastatic unresponsive DTC, we prefer enrollment in a clinical trial of therapies targeting the molecular and cellular pathogenesis of DTC. In patients who are unable to participate in clinical trials, we suggest an oral tyrosine kinase inhibitor (TKI), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , rather than a cytotoxic agent.",
"   </p>",
"   <p>",
"    In the studies described below, the definitions of tumor response are based upon the now-standard Response Evaluation Criteria in Solid Tumors (RECIST), version 1 (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"UTD.htm?41/48/42764\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    (Nexavar) is an oral, small molecule TKI targeting VEGF receptors 2 and 3, common",
"    <span class=\"nowrap\">",
"     RET/PTC",
"    </span>",
"    subtypes, and BRAF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/7\">",
"     7",
"    </a>",
"    ]. Tumor shrinkage was reported in one thyroid cancer patient included in a phase II trial for patients with advanced solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/8\">",
"     8",
"    </a>",
"    ]. Subsequently, phase II trials have been performed focusing on patients with metastatic DTC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/4,9-12\">",
"     4,9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 41 patients with papillary thyroid cancer (PTC), confirmed partial response was seen in 15 percent (with a median time to response of at least one year), and stable disease was described in another 61 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/9\">",
"       9",
"      </a>",
"      ]. For the subgroup of PTC patients whose cancer had not previously been treated with chemotherapy, median progression-free survival (PFS) was 16 months. Another 11 patients had follicular thyroid cancer (FTC) or H&uuml;rthle cell carcinoma; no objective responses were seen, and median PFS was only 4.5 months. Although RAI treatment failure was required as an entry criterion in this trial, demonstration of tumor progression was not required for enrollment.",
"     </li>",
"     <li>",
"      In preliminary results from another trial, unconfirmed partial responses were reported in 4 of 15 (27 percent) evaluable patients with PTC and three of seven with FTC (43 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/10\">",
"       10",
"      </a>",
"      ]. Median PFS was 84 weeks. In an updated report from this ongoing trial, comprising a total of 55 patients (25 with PTC, 19 with FTC or HTC, four with MTC, and five with poorly differentiated or anaplastic carcinomas), the overall PFS remained 84 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/4\">",
"       4",
"      </a>",
"      ]. However, it was significantly shorter (54 weeks) in those patients whose tumors lacked the BRAF activating mutation.",
"     </li>",
"     <li>",
"      Of 32 patients with progressive, radioiodine-negative DTC treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      for 26 weeks, eight (25 percent) patients had a partial response, 11 had stable disease (34 percent), seven had progressive disease (22 percent), and six were non-evaluable [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/11\">",
"       11",
"      </a>",
"      ]. Median PFS was 14.5 months, although patients with bone metastases had significantly worse median PFS than those without (47 weeks compared with 69 weeks). Of 21 patients who underwent radioiodine imaging after 26 weeks of treatment, none had induction of uptake in metastatic lesions. After a median follow-up of 25 months (median sorafenib treatment period of 9.2 months), eight patients had partial response, which were all achieved in the first six months of treatment, and three had stable disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/12\">",
"       12",
"      </a>",
"      ]. Median PFS was 18 months. Disease progression occurred in 15 (58 percent) patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective series comparing rate of disease progression,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    therapy was associated with prolongation of median progression-free survival by at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/13\">",
"     13",
"    </a>",
"    ]. An international, randomized, placebo-controlled phase III study of sorafenib as first-line therapy for progressive metastatic DTC is in progress.",
"   </p>",
"   <p>",
"    The drug may also be appropriate in selected pediatric cases. In one report, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    yielded a marked response in a child whose lung metastases from PTC were progressing despite radioiodine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common or significant toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    therapy included hand-foot syndrome, weight loss, rash, fatigue, diarrhea and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/12\">",
"     12",
"    </a>",
"    ]. Like other agents that inhibit BRAF, sorafenib also has been associated with development of cutaneous squamous cell carcinomas in up to 5 percent of treated patients, and a similar frequency of keratoacanthomas and other premalignant actinic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/15\">",
"     15",
"    </a>",
"    ]. As with other antiangiogenic therapies, pediatric usage may result in bony growth plate inhibition and growth abnormalities.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    is available as treatment for advanced renal cell carcinoma and unresectable hepatocellular carcinoma. Although not specifically approved for thyroid carcinomas, sorafenib (typical starting dose of 400 mg orally twice daily) is being used in selected patients with progressive metastatic papillary thyroid carcinoma for whom clinical trials are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    (Sutent) is an oral, small molecule kinase inhibitor of all three VEGF receptors and",
"    <span class=\"nowrap\">",
"     RET/PTC",
"    </span>",
"    subtypes 1 and 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/18\">",
"     18",
"    </a>",
"    ]. Prolonged partial responses have been described in two DTC patients treated with sunitinib, 50 mg daily for 28 days followed by 14 days of no treatment per cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/19\">",
"     19",
"    </a>",
"    ]. FDG uptake by positron emission tomography imaging was markedly reduced in both patients.",
"   </p>",
"   <p>",
"    Preliminary results from open-label phase II trials in patients with progressive DTC using the same dosing regimen (50 mg daily for 28 days followed by 14 days of no treatment per cycle) are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial response was reported in 13 percent of 31 patients and disease stabilization in another 68 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Partial responses or stable disease for greater than 12 weeks occurred in 17 percent (2 of 12) patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another trial in patients with FDG-PET avid metastatic thyroid cancer, continuous daily dosing (37.5 mg) was assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/22\">",
"     22",
"    </a>",
"    ]. Of 33 patients (26 with DTC), 29 were evaluable for response, and 7 percent had a complete response (lasting at least nine months), 25 percent partial response, and 48 percent stable disease.",
"   </p>",
"   <p>",
"    Common or severe adverse events include fatigue, diarrhea, hand-foot syndrome, neutropenia, and hypertension. Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    is available for treatment of advanced renal cell carcinoma and also for refractory gastrointestinal stromal tumors, but may be considered for use in selected thyroid cancer patients with metastatic disease who cannot participate in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18017769\">",
"    <span class=\"h2\">",
"     Vandetanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    is an oral inhibitor that targets VEGF receptor, RET, and the epidermal growth factor receptor (EGFR). It is available in the United States through a Risk Evaluation and Mitigation Strategy (REMS) program for the treatment of unresectable locally advanced or metastatic medullary thyroid cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=see_link&amp;anchor=H10576313#H10576313\">",
"     \"Chemotherapy and immunotherapy for medullary thyroid cancer\", section on 'Vandetanib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    may also be effective in patients with locally advanced or metastatic differentiated thyroid cancer. In one randomized trial, 145 patients with locally advanced or metastatic differentiated thyroid cancer unresponsive to radioactive iodine were randomly assigned to vandetanib (300 mg once daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/23\">",
"     23",
"    </a>",
"    ]. After a median follow-up of approximately 19 months, fewer patients treated with vandetanib had disease progression (52 versus 61 patients in the placebo group [72 versus 84 percent]). Median progression-free survival was 11.1 and 5.9 months in the vandetanib and placebo groups, respectively (HR 0.63, 95% CI 0.54-0.74). There was no difference in objective partial response (8 percent of 72 and 5 percent of 73 patients, respectively) or overall survival (19 and 21 deaths, respectively). The most common adverse events resulting in discontinuation of vandetanib were prolongation of the QT interval and diarrhea. Additional trials in patients with differentiated thyroid cancer are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    (Votrient) is an orally administered potent small molecule inhibitor of all VEGF receptor subtypes, but has no significant inhibitory activity against the oncogenic kinases RET,",
"    <span class=\"nowrap\">",
"     RET/PTC,",
"    </span>",
"    or BRAF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/24\">",
"     24",
"    </a>",
"    ]. Therefore, its actions are expected to be primarily anti-angiogenic in thyroid carcinoma. In a phase II trial of pazopanib (starting dose 800 mg daily) in 37 patients with rapidly progressing DTC, 49 percent of patients had confirmed partial responses, and the one-year progression-free survival was 47 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common side effects of therapy included hypertension in nearly half, elevated serum transaminases, headache, and mucositis. The drug is available for treatment of advanced renal cell carcinoma, but in the absence of more extensive data in thyroid cancer patients, we do not recommend using the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gefitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     Gefitinib",
"    </a>",
"    (Iressa), an oral, small molecule TKI that targets the epidermal growth factor receptor (EGFR), not VEGF receptor, was initially introduced for therapy of non-small cell lung carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Because many papillary thyroid carcinomas display activated EGFR signaling, and inhibitors demonstrated efficacy in pre-clinical models, an open-label phase II study was initiated, examining the effectiveness of gefitinib (starting dose 250 mg daily) in a mixed cohort of thyroid cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/28\">",
"     28",
"    </a>",
"    ]. Of 27 enrolled patients, two-thirds had either PTC or FTC. There were no complete or partial responses in any of the patients, although eight had minor degrees of tumor reduction. Overall, median progression-free survival was just under four months, but DTC-specific estimates were not reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9541759\">",
"    <span class=\"h2\">",
"     Side effects shared by oral TKIs inhibiting VEGF receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of VEGF-targeted TKIs may include hypertension, renal toxicity, bleeding, myelosuppression, arterial thromboembolism, cardiotoxicity, thyroid dysfunction, cutaneous toxicity including hand-foot skin reaction, delayed wound healing, hepatotoxicity, and muscle wasting. These side effects and their management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=see_link&amp;anchor=H9#H9\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Sorafenib and sunitinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Investigational kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other kinase inhibitors have been studied in clinical trials during the past several years, but these drugs remain investigational at this time and are not available for routine clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2750179\">",
"    <span class=\"h3\">",
"     Antiangiogenic kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the results of these studies support the concept that antiangiogenic kinase inhibitors are useful treatments for advanced or metastatic DTC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multinational phase II trial of motesanib in 93 patients with rapidly progressive DTC, partial response occurred in 14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/5\">",
"       5",
"      </a>",
"      ]. Stable disease lasting more than 24 weeks was also seen in another 35 percent of patients. Partial response or prolonged stable disease was twice as likely in patients with tumors bearing BRAF mutations. Median PFS was 40 weeks.",
"     </li>",
"     <li>",
"      In a multicenter phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      in 45 patients with metastatic DTC, partial response occurred in 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/29\">",
"       29",
"      </a>",
"      ]. Like",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      , axitinib does not have significant anti-RET activity, and therefore its effects are primarily mediated by angiogenesis inhibition.",
"     </li>",
"     <li>",
"      In a phase I study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"       vemurafenib",
"      </a>",
"      (PLX4032), a selective inhibitor of the V600E mutant BRAF kinase, that included three patients with BRAF-mutant metastatic PTC, a partial response was seen in one patient and prolonged stable disease reported in the other two [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/30\">",
"       30",
"      </a>",
"      ]. A larger phase I trial of dabrafenib, another potent BRAF inhibitor, also reported a 33 percent response rate among 12 patients with BRAF-mutant metastatic PTC [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In phase I trials of lenvatinib (an inhibitor of VEGF receptors, RET, and fibroblast growth factor receptors), partial responses in DTC were noted, and an international phase II trial in patients with progressive DTC has been initiated [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11429062\">",
"    <span class=\"h3\">",
"     MEK inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary thyroid cancers frequently carry gene mutations and rearrangements that lead to activation of the mitogen activated protein kinase (MAPK), which promotes cell division and inhibits the sodium-iodide symporter (which usually facilitates iodine uptake) and thyroid peroxidase (facilitates organification). Any given thyroid cancer carries only a single one of these genetic changes, which promote the dedifferentiation of thyroid cancer cells. Thyroid cancers with these mutations are refractory to radioiodine and are associated with a poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=see_link\">",
"     \"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kinase inhibitors targeting MAPK (MEK) are under development for treating metastatic melanoma and other malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100473006#H100473006\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'MEK inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selumetinib is an investigational drug that selectively inhibits MEK 1 and MEK 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/33\">",
"     33",
"    </a>",
"    ]. In a study of 20 patients with radioiodine-refractory papillary thyroid cancer, 12 patients (60 percent) had new",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased radioiodine uptake after treatment with selumetinib (75 mg orally twice daily for four weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/34\">",
"     34",
"    </a>",
"    ]. In eight patients (40 percent), the absorbed radiation dose in the lesion was sufficient enough to continue selumetinib and receive a therapeutic dose of radioiodine. During six months of follow-up, there were partial responses in five patients and stable disease in three. Selumetinib was most effective in patients with NRAS-mutant thyroid cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTHER ANTIANGIOGENIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond direct inhibitors of angiogenic kinases such as vascular endothelial growth factor (VEGF) receptor, other drugs that may be capable of inhibiting angiogenesis have been studied in metastatic thyroid carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thalidomide and lenalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    have antiangiogenic and immunomodulatory effects. The exact mechanism by which these drugs exert their antiangiogenic effects remains unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\", section on 'Thalidomide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link\">",
"     \"Overview of angiogenesis inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an open label, phase II trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in 28 patients with progressive, iodine-unresponsive, metastatic thyroid carcinoma of varying histologies, partial response or durable stable disease was seen in three PTC patients, two FTC patients, three H&uuml;rthle cell cancer patients, and four patients with either tall cell or insular variants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/35\">",
"     35",
"    </a>",
"    ]. Starting at 200 mg daily, the dose of the drug was progressively increased as tolerated, with a median maximum daily dose of about 600 mg. Toxicities were dose limiting in the majority of patients, and the most common adverse events included somnolence, peripheral neuropathy, constipation, dizziness, and infection.",
"   </p>",
"   <p>",
"    Given the suggested efficacy but high rate of adverse events with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , a subsequent phase II study was initiated using the presumably less-toxic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/36\">",
"     36",
"    </a>",
"    ]. Eligibility was limited to DTC patients whose measured tumor volumes had increased by at least 30 percent in the past year. Of 18 evaluable patients, seven (39 percent) had partial responses, with a median duration of 11 months, and another nine (50 percent) were stable. However, median overall survival was less than 11 months, and three patients experienced pulmonary emboli.",
"   </p>",
"   <p>",
"    There are insufficient data to recommend the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    as first-line agents for patients with metastatic DTC, but they may be considered in a clinical trial setting or in patients who have failed kinase inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Celecoxib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon evidence that overexpression of cyclooxygenase-2 (COX-2) in thyroid cancer might stimulate angiogenesis, a phase II trial was performed to evaluate the efficacy of the COX-2 inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    in 32 patients with progressive DTC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/37\">",
"     37",
"    </a>",
"    ]. One patient had a partial response, and one remained stable on therapy for &gt;12 months, but most patients progressed despite treatment. The study was terminated as a result of lack of efficacy combined with increasing concern about cardiovascular toxicity from COX-2 inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CYTOTOXIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although conventional cytotoxic agents are occasionally used for the treatment of patients with progressive symptomatic thyroid cancer that is unresponsive or not amenable to surgery, radioiodine therapy, or external radiotherapy, complete remission is rare, and long-term responses are uncommon. In addition, the availability of tyrosine kinase inhibitors that can stabilize progressive metastatic disease is changing the standard approach to treating these patients, further limiting the role of cytotoxic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Tyrosine kinase inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    is the only cytotoxic agent approved by the US Food and Drug Administration (FDA) for metastatic thyroid cancer. Other single chemotherapeutic agents, including (but not limited to)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and aclarubicin, have not been shown to improve response rates. Similarly, combination therapy with doxorubicin and cisplatin has not been shown to improve the overall response compared with doxorubicin alone, and combination therapy may increase toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, we typically reserve conventional cytotoxic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) for patients with metastatic refractory DTC who are unable to participate in clinical trials or who either cannot tolerate or fail tyrosine kinase inhibitors.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    or other agents may be considered in patients for whom doxorubicin is inappropriate (eg, those with pre-existing impaired cardiac function or myelosuppression). Data regarding combination regimens are even more sparse than for single drugs. Such regimens may be appropriate in select patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , 19 patients with metastatic papillary or follicular carcinoma were enrolled [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/39,42\">",
"     39,42",
"    </a>",
"    ]. Partial responses (defined as &gt;50 percent reduction in tumor area on serial radiographs) to doxorubicin were seen in seven patients (37 percent), and stable disease was reported in another six. Pulmonary metastases appeared to be more likely to respond than bone metastases. By 1974, doxorubicin was considered the \"drug of choice\" for treating progressive, metastatic thyroid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/43\">",
"     43",
"    </a>",
"    ]. Other studies of doxorubicin monotherapy have utilized varying definitions of response, but with similar results (30 to 40 percent partial response) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent report of patients with documented progressive disease prior to chemotherapy, partial response (using WHO criteria) after six months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    treatment was seen in only 5 percent of patients, and stable disease between 1 and 22 months of duration was described in another 42 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/44\">",
"     44",
"    </a>",
"    ]. Response was significantly higher in those patients treated with 60",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    every three weeks, compared with 15",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    weekly. Overall, best responses occurred in patients with pulmonary metastases and high performance status.",
"   </p>",
"   <p>",
"    The recommended dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    for monotherapy is 60 to 75",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    every three weeks, administered as a continuous intravenous infusion for 48 to 72 hours to minimize the risk of cardiac toxicity. Cumulative doses of up to 600",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    can be administered in responsive patients. Common adverse events can include granulocytopenia with accompanying infections, nausea, vomiting, and alopecia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Taxanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of taxanes in differentiated thyroid carcinoma is primarily based upon suggestion of efficacy in anaplastic carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/45\">",
"     45",
"    </a>",
"    ], rather than specific clinical trials. One report described three patients with metastatic differentiated thyroid carcinoma, all of whom had progressed despite radioiodine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/46\">",
"     46",
"    </a>",
"    ]. Biweekly treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    led to disease stabilization in all three, lasting 14 to 18 months, but no objective responses were described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Doxorubicin combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the limited efficacy of monotherapy regimens, the benefit of combinations of chemotherapeutic agents was examined. However, the results of studies evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    combinations were not encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/41,47,48\">",
"     41,47,48",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , 60",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      (initial dose 45",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      if the patient had previously received more than 500 mCi of radioiodine) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , 40",
"      <span class=\"nowrap\">",
"       mg/m2,",
"      </span>",
"      administered every three weeks, was compared with doxorubicin monotherapy in 84 patients with advanced thyroid cancer of any histology [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/41\">",
"       41",
"      </a>",
"      ]. Of the 35 patients with differentiated thyroid carcinoma randomized to treatment, complete or partial response was seen in 16 percent (3 of 19) during combination therapy, whereas doxorubicin alone yielded a 31 percent (5 of 16) partial response rate. Although the difference was not statistically significant, the only complete responses were seen in the combination therapy arm, lasting 33 and 40 months respectively.",
"      <br/>",
"      <br/>",
"      Severe vomiting was more common among patients in the combination therapy arm, but the frequencies of severe hematologic or other life-threatening toxicities were similar in the two cohorts.",
"     </li>",
"     <li>",
"      Adding high dose interferon alpha 2b, 12 million",
"      <span class=\"nowrap\">",
"       units/m2",
"      </span>",
"      on days one through five, to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , 40",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      every 28 days, was minimally effective, yielding only one partial response in 14 evaluable differentiated cancer patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequencies of severe cardiac, neurologic, hematologic, and nephrogenic toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    led to the development of derivatives with less severe adverse events. After anecdotal reports of individual patients who responded to monotherapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , a study was performed to evaluate the efficacy of this combination in patients with radioiodine-refractory thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/49\">",
"     49",
"    </a>",
"    ]. Partial response was only seen in one of nine (11 percent) patients, but stable disease was reported in six (67 percent), with a median duration of 10 months. Toxicities were mild, including grade 3 adverse events in no more than 25 percent of patients.",
"   </p>",
"   <p>",
"    Based on the hypothesis that TSH stimulation could stimulate tumor cell proliferation and therefore enhance effectiveness of cytotoxic chemotherapy, a phase II trial evaluated response to the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    following exogenous or endogenous elevation of TSH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/50\">",
"     50",
"    </a>",
"    ]. Of 16 patients with radioiodine-unresponsive metastases who initiated treatment every four to six weeks with epirubicin 75",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    and carboplatin 400",
"    <span class=\"nowrap\">",
"     mg/m2,",
"    </span>",
"    one (6 percent) had a complete response and five (31 percent) had partial responses. Additional studies are required before this approach can be recommended.",
"   </p>",
"   <p>",
"    No responses were reported in a study of nine patients treated with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Octreotide and radiolabeled octreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin receptor scintigraphy with (111)In-pentetreotide has moderate sensitivity for detecting metastatic DTC (particularly H&uuml;rthle cell carcinomas) and, therefore, it has been hypothesized that the somatostatin analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    would be a useful therapy. However, several reports have indicated the lack of clinical efficacy of this therapy, even in patients with somatostatin-receptor positive metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, in a phase II trial of radiolabeled octreotide, (90)Yttrium-1,4,7,10-tetra-azacyclododecane N,N',N'',N'''-tetraacetic acid [(90)Y-DOTA]-Tyr(3)-octreotide (TOC), there were significant decreases in serum thyroglobulin levels in 7 of 24 patients with metastatic disease detectable by (111)In-pentetreotide imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/54\">",
"     54",
"    </a>",
"    ]. Median survival following radiopeptide therapy was 42 months in those patients whose thyroglobulin levels declined, compared with 14 months for the non-responders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Histone deacetylase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the laboratory, treatment with histone deacetylase (HDAC) inhibitors has been associated with enhanced radioiodine uptake by non-avid cell lines, suggesting improved tumor cell differentiation. The cyclic peptide",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/2/3110?source=see_link\">",
"     romidepsin",
"    </a>",
"    (previously known as depsipeptide) selectively inhibits four isotypes of histone deacetylases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/55\">",
"     55",
"    </a>",
"    ]. The results of clinical trials using this agent, however, have been disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. As an example, in a phase II trial in 20 patients with radioiodine-unresponsive, progressive metastatic DTC, no objective tumor responses were reported, and 10 patients achieved stable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/57\">",
"     57",
"    </a>",
"    ]. Two patients exhibited restoration of radioiodine uptake permitting therapeutic radioiodine administration. Significant cardiac toxicities were seen, including sudden death in one patient and a grade 4 pulmonary embolus in another.",
"   </p>",
"   <p>",
"    Similar findings were noted with another histone deacetylase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/29/27093?source=see_link\">",
"     vorinostat",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/58\">",
"     58",
"    </a>",
"    ]. None of the 16 patients with advanced DTC achieved a partial or complete remission, and most patients discontinued therapy due to progressive disease or adverse events, including fatigue, dehydration, ataxia, pneumonia, bruises, deep vein thrombosis, and severe thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUGGESTED APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of tyrosine kinase inhibitors that can stabilize progressive metastatic disease has changed the standard approach to treating patients whose disease no longer responds to radioiodine and TSH-suppressive hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Although it may take many months before radiographic response becomes evident, targeting angiogenesis (and specifically VEGFR signaling pathways) has produced the most impressive clinical responses to date in DTC.",
"   </p>",
"   <p>",
"    However, these drugs are disease-modifying agents, usually tumoristatic rather than tumoricidal, and no published study has evaluated these agents' ability to improve survival. In addition, these newer \"targeted therapies\" have significant toxicities and, therefore, it is important to limit the use of systemic treatments to patients at significant risk for morbidity or mortality due to progressive metastatic disease. Patients treated with systemic agents should have a baseline performance status sufficiently functional to tolerate these interventions, such as being ambulatory at least 50 percent of the day (ECOG performance status 2 or better).",
"   </p>",
"   <p>",
"    In the absence of sufficient clinical trial data comparing both efficacy and safety of any individual drug or combination, the following treatment strategy is based upon clinical experience and data from open label studies. Our approach is consistent with the American Thyroid Association Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28345/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with asymptomatic metastatic tumors generally less than 1 to 2 cm in diameter, growing in diameter less than 20 percent per year, we suggest continued treatment with TSH suppression (with TSH levels as low as the patient can tolerate). Known sites of metastatic disease should be imaged by CT or MRI every six months, and potential new sites of disease should be imaged every 12 to 24 months.",
"     </li>",
"     <li>",
"      For patients with metastatic tumors at least 1 to 2 cm in diameter, growing by at least 20 percent per year, or for patients with symptoms related to multiple metastatic foci that cannot be alleviated with surgery or external beam radiotherapy, we prefer to administer systemic treatment in the context of a clinical trial. (Active clinical trials can be identified at:",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=thyroid+cancer&amp;recr=Open\">",
"       file://www.clinicaltrials.gov/ct2/results?term=thyroid+cancer&amp;recr=Open",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who cannot participate in a clinical trial, we suggest oral tyrosine kinase inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    . For patients who cannot tolerate or who fail tyrosine kinase inhibitors, we suggest cytotoxic chemotherapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with metastatic differentiated thyroid carcinoma (DTC) that persists despite radioiodine, TSH-suppressive thyroid hormone therapy, and external radiotherapy, treatment options include observation, traditional cytotoxic chemotherapy, and novel therapies (eg, tyrosine kinase inhibitors) that primarily target angiogenesis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Suggested approach'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"       \"Overview of the management of differentiated thyroid cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Considerable evidence points to the involvement of tyrosine kinases in the pathogenesis of a variety of solid tumors. Multitargeted kinase inhibitors that directly inhibit the activity of the tyrosine kinases have been successful in treating some cancers, and they hold promise for the treatment of refractory metastatic DTC. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Tyrosine kinase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with stable metastatic disease (tumors &lt;1 to 2 cm and growing less than 20",
"      <span class=\"nowrap\">",
"       percent/year),",
"      </span>",
"      we suggest NOT using systemic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). These patients should remain on TSH suppression therapy. We perform imaging studies every six months to monitor for disease progression. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with metastatic unresponsive DTC (tumors &gt;1 to 2 cm and growing by at least 20",
"      <span class=\"nowrap\">",
"       percent/year)",
"      </span>",
"      or symptomatic metastatic disease, we prefer to enroll patients in clinical trials of therapies targeting the molecular and cellular pathogenesis of DTC. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with metastatic unresponsive DTC (tumors &gt;1 to 2 cm and growing by at least 20",
"      <span class=\"nowrap\">",
"       percent/year)",
"      </span>",
"      or symptomatic metastatic disease who are unable to participate in clinical trials, we suggest an oral tyrosine kinase inhibitor, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      , rather than a cytotoxic agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      is an alternative for patients who are unable to tolerate or who fail therapy with kinase inhibitors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Tyrosine kinase inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/1\">",
"      Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/2\">",
"      Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/3\">",
"      Schlumberger M, Sherman SI. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 2009; 19:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/4\">",
"      Brose, MS, Troxel, AB, Redlinger, M, et al. Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. J Clin Oncol (Meeting Abstracts) 2009; 27:6002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/5\">",
"      Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/6\">",
"      Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/7\">",
"      Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/8\">",
"      Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/9\">",
"      Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/10\">",
"      Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26:4714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/11\">",
"      Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/12\">",
"      Schneider TC, Abdulrahman RM, Corssmit EP, et al. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012; 167:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/13\">",
"      Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010; 95:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/14\">",
"      Waguespack SG, Sherman SI, Williams MD, et al. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid 2009; 19:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/15\">",
"      Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009; 7:20.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/17\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/18\">",
"      Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91:4070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/19\">",
"      Dawson SJ, Conus NM, Toner GC, et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 2008; 19:547.",
"     </a>",
"    </li>",
"    <li>",
"     Cohen, EE, Needles, BM, Cullen, KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol (Meeting Abstracts) 2008; 26.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/21\">",
"      Ravaud, A, de la Fouchardi&egrave;re, C, Courbon, F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol (Meeting Abstracts) 2008; 26:6058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/22\">",
"      Carr, L, Goulart, B, Martins, R, et al. Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC). J Clin Oncol (Meeting Abstracts) 2009; 27:6056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/23\">",
"      Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/24\">",
"      Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/25\">",
"      Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010; 11:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/26\">",
"      Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/27\">",
"      Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/28\">",
"      Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008; 18:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/29\">",
"      Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26:4708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/30\">",
"      Flaherty, K, Puzanov, I, Sosman, J, et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol (Meeting Abstracts) 2009; 27:9000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/31\">",
"      Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/32\">",
"      Nemunaitis, JJ, Senzer, NN, Kurzrock, R, et al. Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2008; 26:14583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/33\">",
"      Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 2012; 18:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/34\">",
"      Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013; 368:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/35\">",
"      Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007; 17:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/36\">",
"      Ain, KB, Lee, C, Holbrook, KM, et al. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. J Clin Oncol (Meeting Abstracts) 2008; 26:6027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/37\">",
"      Mrozek E, Kloos RT, Ringel MD, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/38\">",
"      Bonadonna G, Monfardini S, De Lena M, et al. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 1970; 30:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/39\">",
"      Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 1974; 290:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/40\">",
"      Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999; 16:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/41\">",
"      Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56:2155.",
"     </a>",
"    </li>",
"    <li>",
"     Burgess MA, Hill CS Jr. Chemotherapy in the management of thyroid cancer. In: Thyroid Cancer, Greenfield LD (Ed), CRC Press, W. Palm Beach, FL 1978. p.233.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/43\">",
"      Carter SK, Blum RH. New chemotherapeutic agents--bleomycin and adriamycin. CA Cancer J Clin 1974; 24:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/44\">",
"      Matuszczyk A, Petersenn S, Bockisch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008; 40:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/45\">",
"      Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000; 10:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/46\">",
"      Ikeda M, Tanaka K, Sonoo H, et al. [Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma]. Gan To Kagaku Ryoho 2007; 34:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/47\">",
"      Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/48\">",
"      Argiris A, Agarwala SS, Karamouzis MV, et al. A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 2008; 26:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/49\">",
"      Biganzoli L, Gebbia V, Maiorino L, et al. Thyroid cancer: different outcomes to chemotherapy according to tumour histology. Eur J Cancer 1995; 31A:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/50\">",
"      Santini F, Bottici V, Elisei R, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 2002; 87:4160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/51\">",
"      Matuszczyk A, Petersenn S, Voigt W, et al. Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2010; 42:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/52\">",
"      Zlock DW, Greenspan FS, Clark OH, Higgins CB. Octreotide therapy in advanced thyroid cancer. Thyroid 1994; 4:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/53\">",
"      Kohlfuerst S, Igerc I, Gallowitsch HJ, et al. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases? Thyroid 2006; 16:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/54\">",
"      Iten F, Muller B, Schindler C, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer 2009; 115:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/55\">",
"      Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009; 280:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/56\">",
"      Piekarz, R, Luchenko, V, Draper, D, et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. J Clin Oncol 2008; 28:3571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/57\">",
"      Sherman, EJ, Fury, MG, Tuttle, RM, et al. Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. J Clin Oncol (Meeting Abstracts) 2009; 27:6059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28345/abstract/58\">",
"      Woyach JA, Kloos RT, Ringel MD, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009; 94:164.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2191 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28345=[""].join("\n");
var outline_f27_43_28345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYROSINE KINASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sunitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18017769\">",
"      Vandetanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gefitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9541759\">",
"      Side effects shared by oral TKIs inhibiting VEGF receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Investigational kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2750179\">",
"      - Antiangiogenic kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11429062\">",
"      - MEK inhibition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTHER ANTIANGIOGENIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thalidomide and lenalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Celecoxib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CYTOTOXIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Doxorubicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Taxanes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Doxorubicin combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other combinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MISCELLANEOUS AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Octreotide and radiolabeled octreotide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Histone deacetylase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUGGESTED APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2191\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2191|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/48/42764\" title=\"table 1\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23721?source=related_link\">",
"      Anaplastic thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=related_link\">",
"      Chemotherapy and immunotherapy for medullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39191?source=related_link\">",
"      External beam radiotherapy in the treatment of thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=related_link\">",
"      Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=related_link\">",
"      Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=related_link\">",
"      Radioiodine treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_43_28346="Osteonecrosis (avascular necrosis of bone)";
var content_f27_43_28346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Osteonecrosis (avascular necrosis of bone)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28346/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28346/contributors\">",
"     Lynne C Jones, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28346/contributors\">",
"     Michael A Mont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28346/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28346/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/43/28346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/43/28346/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/43/28346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis, also known as aseptic necrosis, avascular necrosis (AVN), atraumatic necrosis, and ischemic necrosis, is a pathologic process that has been associated with numerous conditions and therapeutic interventions. In patients in whom there is direct damage to bone vasculature (eg, femoral neck fracture) or direct injury of bone or marrow elements (eg, radiation injury, dysbarism, or caisson disease), the cause is clearly identifiable. However, in many patients, the mechanisms by which this disorder develops are not fully understood.",
"   </p>",
"   <p>",
"    Compromise of the bone vasculature, leading to the death of bone and marrow cells (bone marrow infarction), and ultimate mechanical failure appear to be common to most proposed etiologies. The process is most often progressive, resulting in joint destruction within a few months to two years in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18899891\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact prevalence of osteonecrosis is unknown. In the United States, there are an estimated 10,000 to 20,000 patients newly diagnosed each year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/3\">",
"     3",
"    </a>",
"    ], and osteonecrosis is the underlying diagnosis in approximately 10 percent of all total hip replacements [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/4\">",
"     4",
"    </a>",
"    ]. The male-to-female ratio varies depending upon the associated comorbidities. For example, alcohol-associated osteonecrosis is more common in men, while osteonecrosis associated with systemic lupus erythematosus (SLE) is more common in women. The mean age at diagnosis also depends upon comorbidities but is typically less than 40 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of traumatic and atraumatic factors contribute to the etiology of osteonecrosis (",
"    <a class=\"graphic graphic_table graphicRef69502 \" href=\"UTD.htm?38/56/39819\">",
"     table 1",
"    </a>",
"    ). A definitive etiologic role has been established for some of these factors but not for the majority, which are considered associated risk factors. Use of corticosteroids and excessive alcohol intake are associated with more than 80 percent of atraumatic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of osteonecrosis is an area of controversy. Most experts believe that it is the result of the combined effects of genetic predisposition, metabolic factors, and local factors affecting blood supply, such as vascular damage, increased intraosseous pressure, and mechanical stresses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. It probably begins by an interruption of the blood circulation within the bone; subsequently, the adjacent area becomes hyperemic, resulting in demineralization, in trabecular thinning, and, later, in collapse.",
"   </p>",
"   <p>",
"    The histopathologic finding of bone marrow infarction has been noted in marrow samples from patients with some of the same disorders that cause clinically apparent osteonecrosis, but neoplastic disorders, particularly hematologic and lymphoid malignancies and metastatic cancer with associated coagulopathy, are other potential etiologies. The causes of bone marrow infarction (bone marrow necrosis) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of bone marrow aspirate smears\", section on 'Bone marrow necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies relate the use of corticosteroids to the development of osteonecrosis. Many of these are small retrospective series and case reports with anecdotal evidence and with poor controls. In one study of 1199 joints in 302 patients, the incidence of developing osteonecrosis as a consequence of these medications ranged from 21 to 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/6\">",
"     6",
"    </a>",
"    ]; the frequency varies, depending, in part, upon the associated comorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the pathogenesis of osteonecrosis is unknown, there are several mechanisms that have been proposed. One possible mechanism of corticosteroid-associated osteonecrosis involves alterations in circulating lipids with resultant microemboli in the arteries supplying bone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/9\">",
"     9",
"    </a>",
"    ]. Another is that an increase in bone marrow fat cell size and number contributes to blocking venous flow [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/10\">",
"     10",
"    </a>",
"    ]. A more recent theory proposes that corticosteroids induce changes in venous endothelial cells, leading to stasis, to increased intraosseous pressure, and to eventual necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients treated with prolonged high doses of corticosteroids appear to be at the greatest risk of developing osteonecrosis; however, these patients often have multiple other risk factors. Even patients receiving chronic physiologic corticosteroid replacement for adrenal insufficiency may develop osteonecrosis (2.4 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/12\">",
"     12",
"    </a>",
"    ]. However, osteonecrosis generally does not result from short-term use of these medications. In previous anecdotal reports suggesting an association, multiple additional risk factors were also present, suggesting that it was highly unlikely that these low doses lead to the disease.",
"   </p>",
"   <p>",
"    Most studies have found that the risk is low (less than 3 percent) in patients treated with doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    less than 15 to 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    In one series, the prednisone dose in the highest month of therapy exceeded 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in 93 percent and 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in 100 percent of patients with osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/13\">",
"     13",
"    </a>",
"    ]. The only clinical finding that distinguished patients with osteonecrosis from those without this complication was a Cushingoid appearance (86 versus 15 percent).",
"   </p>",
"   <p>",
"    It has been suggested that the initial corticosteroid dose may be more important than the total dose or duration of therapy. One report, for example, evaluated 17 patients with SLE who developed osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/14\">",
"     14",
"    </a>",
"    ]. The corticosteroid dose during the initial period of therapy was compared with that of 25 control patients with SLE. The patients with osteonecrosis had received a substantially higher dose of corticosteroids in the first one, three, and six months of therapy. In comparison, the duration of therapy did not correlate with osteonecrosis, and total corticosteroid exposure was virtually identical in both groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive alcohol use and the development of osteonecrosis have long been linked; fat emboli, adipocyte hypertrophy, venous stasis, and increased cortisol levels have all been implicated as etiologic factors. While only a small percentage of alcoholics develop osteonecrosis, alcohol has been considered an associated risk factor in up to 31 percent of the osteonecrosis patients evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. One epidemiologic study compared 112 patients who had idiopathic osteonecrosis of the femoral head and no history of systemic corticosteroid use with 168 hospital controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/15\">",
"     15",
"    </a>",
"    ]. An elevated risk for regular drinkers and a clear dose-response relationship were noted; the relative risks were 3.3, 9.8, and 17.9 for current consumers of less than 400",
"    <span class=\"nowrap\">",
"     mL/week,",
"    </span>",
"    400 to 1000",
"    <span class=\"nowrap\">",
"     mL/week,",
"    </span>",
"    and more than 1000",
"    <span class=\"nowrap\">",
"     mL/week",
"    </span>",
"    of alcohol, respectively, compared with controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis has been reported in 3 to 30 percent of patients with systemic lupus erythematosus (SLE) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. This wide range reflects the use of different techniques in defining this disorder (from the less sensitive plain film radiograph to the quite sensitive magnetic resonance imaging [MRI]), variations in corticosteroid dosing, and different durations of follow-up. One report followed 228 patients with SLE for a mean period of 31 months. Nine percent had osteonecrosis, and it was estimated that the frequency would rise to 30 percent at 10 to 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with SLE who have taken corticosteroids are at greatest risk, although occasional cases have been noted in the absence of this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/14,18,19\">",
"     14,18,19",
"    </a>",
"    ]. Osteonecrosis often develops in patients with SLE a relatively short time after the onset of corticosteroid therapy. One prospective study, for example, evaluated 60 patients with SLE over a period of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/19\">",
"     19",
"    </a>",
"    ]. Those who had no MRI abnormalities in the femoral head during the first year of follow-up were unlikely to develop osteonecrosis at a later date.",
"   </p>",
"   <p>",
"    Other risk factors for osteonecrosis have also been identified in SLE. These include regular doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    greater than 20",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    evidence of corticosteroid-associated end organ effect, Raynaud phenomenon, and hyperlipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/20\">",
"     20",
"    </a>",
"    ]. There are conflicting data on the role of antiphospholipid antibodies in lupus; some data support an association [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], while other data do not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional associations have been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], including African-American origin, Cushingoid habitus, vasculitis, pleuritis, and central nervous system (CNS) involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their potential role in patients with SLE, antiphospholipid antibodies may be associated with an increased risk of osteonecrosis in other individuals. This was illustrated in a study of 45 patients who had osteonecrosis, only nine of whom had SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/24\">",
"     24",
"    </a>",
"    ]. The prevalence of antiphospholipid antibodies was more than threefold greater among 45 patients with osteonecrosis compared with 40 healthy controls (34 versus 10 percent). However, as with patients with SLE, not all data regarding the risk of osteonecrosis in patients with primary antiphospholipid syndrome are concordant, suggesting, at best, a weak association [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fracture or dislocation may cause damage to the extraosseous blood vessels supplying the affected region. Fractures in the subcapital region of the femoral neck, for example, frequently interrupt the major part of the blood supply to the head of the femur, which can result in ischemia and in bone necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/26\">",
"     26",
"    </a>",
"    ]. At the wrist, fractures of the scaphoid and lunate are associated with an increased risk of osteonecrosis. In some cases of osteonecrosis of the lunate (also known as Kienb&ouml;ck's disease), no identifiable single traumatic event can be identified, and repetitive injury or stress fracture is suspected as the cause in these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sickle cell hemoglobinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis is common in patients with homozygous sickle cell disease due to red blood cell sickling and to bone marrow hyperplasia. Approximately 50 percent of affected patients develop osteonecrosis by the age of 35 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Bone complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18506?source=see_link\">",
"     \"Bone and joint complications in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gaucher disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gaucher disease is a hereditary (autosomal recessive) disorder of glucocerebroside metabolism, which results in the accumulation of cerebroside-filled cells within the bone marrow. This process may lead to compression of the vasculature and to subsequent osteonecrosis. Osteonecrosis has been reported in 60 percent of patients with Gaucher disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Decompression disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased pressure associated with decompression disease (also called dysbarism and caisson disease) can lead to the formation of nitrogen bubbles that can occlude arterioles and that can cause osteonecrosis. Symptomatic osteonecrosis can develop years after the exposure; the number of exposures and the magnitude of depth and of pressure are important risk factors. Elevated plasma levels of plasminogen activator inhibitor (PAI-1) may also increase risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis is a quite debilitating musculoskeletal complication following renal transplantation. It is usually multifocal in this setting, with 50 to 70 percent of affected patients having more than one joint involved. Previous studies suggested an incidence of approximately 15 percent within three years of the transplant; however, the risk decreased following the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (with consequent decreases in corticosteroid dosing) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. A prospective study of 48 patients without evidence of femoral osteonecrosis prior to renal transplantation noted an incidence of 4 percent when examined by MRI at six months following the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether osteopenia and preexisting hyperparathyroidism are independent risk factors in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=see_link\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteonecrosis may also occur with other types of transplantation, such as hematopoietic cell transplantation (HCT). As an example, one study surveyed the prevalence of osteonecrosis among 207 patients undergoing HCT for lymphoproliferative or myeloproliferative diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/34\">",
"     34",
"    </a>",
"    ]; patients receiving allogeneic HCT were more often affected than those receiving autologous HCT (10 versus 2 percent). The duration and cumulative dose of corticosteroids, as well as the presence of graft-versus-host disease, were risk factors for the development of this complication.",
"   </p>",
"   <p>",
"    Among allogeneic HCT recipients, the risk of osteonecrosis may also be dependent upon the sex of the donor and the recipient, as well as the disease for which HCT is being performed. This was illustrated in a study of 255 patients who underwent allogeneic HCT for one of a variety of hematologic disorders and who were evaluated for osteonecrosis of the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/35\">",
"     35",
"    </a>",
"    ]. The following risk factors were noted in addition to corticosteroid exposure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall incidence of osteonecrosis of the hip was 6 percent during four years of post-transplant observation, but there were no cases among the 152 patients transplanted for chronic myeloid leukemia. The incidence in the remaining patients was 20 percent (13 percent in 70 patients with acute myeloid leukemia, 28 percent in 13 patients with myelodysplastic disorders, and 37 percent in 20 patients with acute lymphoblastic leukemia).",
"     </li>",
"     <li>",
"      Female donor to female recipient transplantation carried the highest risk of osteonecrosis with more than 40 percent of such patients requiring hip replacement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435805\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inherited thrombophilia and hypofibrinolysis &mdash; There are conflicting data from small retrospective series regarding the role of mutations in genes for proteins in the coagulation and fibrinolytic pathways in the pathogenesis of osteonecrosis. Four reports suggested an increased prevalence of the factor V Leiden mutation in patients with osteonecrosis of the hip or knee compared with healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/36-39\">",
"       36-39",
"      </a>",
"      ], a finding that was not seen in another study [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/24\">",
"       24",
"      </a>",
"      ]. In the last study, an elevation in the hypofibrinolytic plasminogen activator inhibitor was found more frequently in cases than in controls (42 versus 3 percent, respectively). No statistically significant association was noted in these series with prothrombin or methylenetetrahydrofolate reductase mutations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HIV infection &mdash; Infection with the human immunodeficiency virus (HIV) may confer an increased risk of developing osteonecrosis of the femoral head. In one case-control study, the point prevalence of osteonecrosis that was apparent on MRI was 4 percent among 339 HIV-infected patients, while no osteonecrosis was found in 118 gender- and age-matched healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/40\">",
"       40",
"      </a>",
"      ]. Additional risk factors in the HIV infected population may be the use of corticosteroids, lipid-lowering drugs, testosterone, and weight training. Use of highly active antiretroviral therapy (HAART) does not appear to be an independent risk factor [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiation therapy &mdash; Osteonecrosis may result from external beam radiation therapy (osteoradionecrosis). Osteoradionecrosis of the mandible may complicate treatment of head and neck cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822453#H3822453\">",
"       \"Management of late complications of head and neck cancer and its treatment\", section on 'Osteoradionecrosis and soft tissue necrosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heritable osteonecrosis &mdash; Rarely, osteonecrosis of the femoral head occurs as a heritable disorder. In one study of three affected Chinese families, mutations were present in the gene for the alpha chain of type II collagen (COL2A1) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/42\">",
"       42",
"      </a>",
"      ]. However, no mutations in the COL2A1 gene were found in 65 patients with sporadic osteonecrosis of the femoral head. Substitution of serine for glycine in a portion of the molecule that forms an extended triple helical portion was predicted to result from the observed mutations.",
"      <br/>",
"      <br/>",
"      The same COL2A1 mutation described above can be associated with at least three different clinical presentations. This was observed in another Chinese family that included individuals with premature osteoarthritis, osteonecrosis of the femoral head, or Legg-Calv&eacute;-Perthes disease, which were diagnosed, respectively, in young adults, adolescents, or children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/43\">",
"       43",
"      </a>",
"      ]. Legg-Calv&eacute;-Perthes disease has also been reported in members of a Japanese family [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Children'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Bisphosphonate use &mdash; Use of bisphosphonates, particularly in patients with malignant diseases such as multiple myeloma and metastatic breast cancer, has been suggested as a risk factor for the development of osteonecrosis of the jaw. This disorder has been likened to radiation-induced osteonecrosis of the jaw and presents with nonhealing of the socket following tooth extraction or with exposed jaw bone. Osteonecrosis of the jaw is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H48#H48\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Osteonecrosis of the jaw'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the various disorders that may affect both adults and children, there are two types of osteonecrosis that are limited to children: idiopathic osteonecrosis of the femoral head (Legg-Calv&eacute;-Perthes disease) and osteonecrosis occurring in children, usually adolescents, with a slipped capital femoral epiphysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of hip pain in childhood\", section on 'Legg-Calv&eacute;-Perthes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link&amp;anchor=H21#H21\">",
"     \"Slipped capital femoral epiphysis (SCFE)\", section on 'Osteonecrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diagnosis of osteonecrosis may provide the opportunity to prevent collapse and, ultimately, the need for joint replacement. However, most patients present late in the course of the disease. Thus, a high index of suspicion is necessary for those with known or probable risk factors, particularly high-dose corticosteroid use.",
"   </p>",
"   <p>",
"    Osteonecrosis usually occurs in the anterolateral femoral head, although it may also affect the femoral condyles, humeral heads, proximal tibia, vertebrae, and small bones of the hand and foot [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/5\">",
"     5",
"    </a>",
"    ]. Many patients have bilateral involvement at the time of diagnosis, including disease of the hips, knees, and shoulders. In patients who present with osteonecrosis of the knee, shoulder, or other non-hip joint, the hip should be evaluated clinically and by imaging. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Physical findings'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting symptom of osteonecrosis is pain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Groin pain is most common in patients with femoral head disease, followed by thigh and buttock pain.",
"     </li>",
"     <li>",
"      Weightbearing or motion-induced pain is found in most cases.",
"     </li>",
"     <li>",
"      Rest pain occurs in approximately two-thirds of patients, and night pain occurs in one-third.",
"     </li>",
"     <li>",
"      Rarely, pain in many joints suggests a multifocal process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of patients are asymptomatic; in these cases, the diagnosis is usually incidental. Asymptomatic involvement contralateral to a symptomatic site is frequently noted. The therapeutic implications of the finding of radiographic or MRI evidence of asymptomatic osteonecrosis are uncertain. However, a 2010 systematic review of 16 reports found that over 60 percent of asymptomatic hips progressed to collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical findings are largely nonspecific. Patients with hip disease may have pain and, eventually, limitations of range of motion, particularly with forced internal rotation and abduction. A limp may be present late in the course of lower extremity disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The features of osteonecrosis on plain film radiographs, radionuclide scans, and MRI are helpful diagnostically and provide the basis for classification and staging systems. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Classification systems and staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Plain film radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation for suspected osteonecrosis of the femoral head should begin with anterior-posterior and frog-leg lateral films. Lateral films are necessary to evaluate the superior portion of the femoral head in which subchondral abnormalities are often seen.",
"   </p>",
"   <p>",
"    The plain radiograph can remain normal for months after symptoms of osteonecrosis begin; the earliest findings are mild density changes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79133 graphicRef69304 \" href=\"UTD.htm?13/27/13746\">",
"     image 1A-B",
"    </a>",
"    ), followed by sclerosis and cysts as the disease progresses. The pathognomonic crescent sign (subchondral radiolucency) is evidence of subchondral collapse. Later stages reveal loss of sphericity or collapse of the femoral head. Ultimately, joint-space narrowing and degenerative changes in the acetabulum are visible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Radionuclide bone scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technetium-99m bone scanning has been used for patients with suspected disease who have negative radiographs, unilateral symptoms, and no risk factors. Increased bone turnover at the junction of dead and reactive bone results in increased uptake surrounding a cold area; this has been called the doughnut sign [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/49\">",
"     49",
"    </a>",
"    ]. However, bone scanning, performed in 48 patients with suspected osteonecrosis of the shoulder, hip, knee, or ankle, was less sensitive than MRI (56 versus 100 percent) in diagnosing histologically-confirmed osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/50\">",
"     50",
"    </a>",
"    ]. Sensitivity was least in patients with early-stage lesions. Thus, we do not use bone scanning for the diagnosis of or screening for osteonecrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     MR imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is far more sensitive than plain radiographs or bone scanning, with reported sensitivity of up to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/5,50,51\">",
"     5,50,51",
"    </a>",
"    ]. Changes can be seen early in the course of disease when other studies are negative.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal lesions are well-demarcated and inhomogeneous on T-1 weighted images. The earliest finding is a single density line (low intensity signal) that represents the separation of normal and ischemic bone.",
"     </li>",
"     <li>",
"      A second high intensity line appears on T-2 weighted images, representing hypervascular granulation tissue; this is the pathognomonic double-line sign (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58502 \" href=\"UTD.htm?17/7/17523\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI has largely replaced measurement of bone marrow pressure, venography, and bone biopsy as a means of diagnosing early stage osteonecrosis. However, there must be some caution in interpreting MRI findings, particularly in asymptomatic patients. One study, for example, evaluated 23 corticosteroid-treated patients with SLE who had no hip pain and a negative hip plain radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/53\">",
"     53",
"    </a>",
"    ]. Over a three-year period, only two of the eight patients with an initially abnormal MRI developed a lesion detectable by conventional hip radiographs. Thus, surgical treatment based upon abnormal MRI findings alone, in the absence of symptoms, can potentially result in overtreatment of some patients. However, treatment is never based solely upon an imaging study. Size of the lesion, location of the lesion, age of the patient, general health, and symptoms, if present, also influence treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amount of femoral head involvement estimated by MRI may be indicative of the likelihood of subsequent collapse. As an example, in a study of 37 hips with early osteonecrosis, the sum of the angles subtended by involved bone (measured from near the center of the femoral head in the sagittal and coronal views) correlated with subsequent subchondral collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/55\">",
"     55",
"    </a>",
"    ]. Among those hips with a sum of &le;190 degrees, none collapsed during up to five years of follow-up. In contrast, all of the hips with a sum of &ge;240 degrees progressed to collapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119498333\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis is appropriately made in a symptomatic patient when MRI or radiographic imaging findings are compatible with this disease and when other causes of pain and bony abnormalities either are unlikely or have been excluded by appropriate testing. MRI continues to be the &ldquo;gold standard&rdquo; for diagnosis in symptomatic and asymptomatic patients, especially in early stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of pain with characteristics that suggest an osteoarticular origin and with imaging features compatible with osteonecrosis is discussed below. General approaches to the evaluation of patients with site-specific (eg, hip, shoulder, etc) pain are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=see_link\">",
"     \"Evaluation of the adult with polyarticular pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link\">",
"     \"Evaluation of the adult with hip pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link\">",
"     \"Overview of hip pain in childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Bone marrow edema syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow edema syndrome (BMES), also known as transient osteopenia of the hip (TOH), may occur in isolation or in association with injuries, particularly those that result in neurologic damage. In the latter situation, chronic pain and transient osteopenia are features of the complex regional pain syndrome (also known as reflex sympathetic dystrophy, causalgia, and other terms). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the hip is affected by BMES, MRI findings suggestive of BMES (decreased signal on T1-weighted images and increased intensity on T2-weighted images) may extend from the femoral head into the femoral neck. An effusion may be present. The absence of fever, leukocytosis, or elevation of acute phase reactants (erythrocyte sedimentation rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C reactive protein) is characteristic of both osteonecrosis and BMES and helps to exclude an infectious etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=see_link&amp;anchor=H16#H16\">",
"     \"Radiologic evaluation of the painful hip in adults\", section on 'Bone marrow edema syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Subchondral fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subchondral fracture of the femoral head typically occurs in patients with preexisting osteopenia and is thought, in most cases, to represent an insufficiency fracture. Such fractures may be difficult to visualize with plain radiographs. Subtle flattening is sometimes present with early lesions; collapse is progressive. Linear regions of low signal on both T1- and T2-weighted MR images in the subchondral area that parallel the articular surface are characteristic of these rare fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. There is a growing recognition that most patients diagnosed with spontaneous osteonecrosis of the knee (sometimes called SPONK) actually have insufficiency fractures as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     CLASSIFICATION SYSTEMS AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification systems for staging of osteonecrosis have been based either upon pathologic findings or upon imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Pathologic staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic findings are similar in all cases of osteonecrosis, regardless of the etiology. A classification scheme was proposed in the early 1970s that is useful for pathologic purposes, but it does not correlate with the radiographic stage of disease or with symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I &mdash; Prenecrotic, interstitial edema or plasmastasis confined to the bone marrow with occasional foam cells seen",
"     </li>",
"     <li>",
"      Type II &mdash; Medullary spaces filled with necrotic tissue",
"     </li>",
"     <li>",
"      Type III &mdash; Marrow necrosis associated with trabecular necrosis, with up to 100 percent of lacunae being empty",
"     </li>",
"     <li>",
"      Type IV &mdash; Complete necrosis with dense medullary fibrosis and new bone formation on dead trabeculae",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any or all pathologic types can be seen in one specimen depending upon sampling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Clinical staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous staging systems for osteonecrosis of the femoral head have been developed since the first one was described by Ficat and Arlet, which was based solely upon radiographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/60-65\">",
"     60-65",
"    </a>",
"    ]. Newer imaging modalities, such as computerized tomography and magnetic resonance imaging, and the need for quantification of involvement have led to these revisions. Furthermore, the importance of the size and extent of the lesion in the prognosis of various treatments was also recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/66\">",
"     66",
"    </a>",
"    ]. The",
"    <a class=\"external\" href=\"file://arco-intl.org/Newsletters/Gardeniers-1993-5-2/Gardeniers-1993.htm\">",
"     Association of Research Circulation Osseous (ARCO) staging system",
"    </a>",
"    in was developed in an attempt to bring uniformity to clinical trials of treatment strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/3,67,68\">",
"     3,67,68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 0 &mdash; All diagnostic studies normal and diagnosis by histology only",
"     </li>",
"     <li>",
"      Stage 1 &mdash; Plain radiographs and computed tomography normal, magnetic resonance imaging positive, and biopsy positive, with extent of involvement A, B, or C (less than 15 percent, 15 to 30 percent, and greater than 30 percent, respectively)",
"     </li>",
"     <li>",
"      Stage 2 &mdash; Radiographs positive but no collapse (",
"      <strong>",
"       no",
"      </strong>",
"      crescent sign), with extent of involvement A, B, or C",
"     </li>",
"     <li>",
"      Stage 3 &mdash; Early flattening of dome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      crescent sign on plain radiography or by computed tomography or tomograms, with extent of involvement A, B, or C and further characterization by amount of depression (in millimeters) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79910 \" href=\"UTD.htm?31/59/32702\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stage 4 &mdash; Flattening of femoral head with joint space narrowing on plain radiography, as well as other signs of osteoarthritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of osteonecrosis remains one of the most controversial subjects in the orthopedic literature. The goal of therapy is to preserve the native joint for as long as possible. There are three main therapeutic options:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonoperative management",
"     </li>",
"     <li>",
"      Joint-preserving procedures",
"     </li>",
"     <li>",
"      Joint replacement",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194050126\">",
"    <span class=\"h2\">",
"     Nonoperative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonoperative management for osteonecrosis of the hip or knee, which includes bed rest, partial weightbearing with crutches, weightbearing as tolerated, and use of nonsteroidal antiinflammatory drugs (NSAIDs) or other analgesics, has generally been ineffective at halting the progression of disease.",
"   </p>",
"   <p>",
"    A 1996 meta-analysis of 21 studies looking at nonoperative treatment in 819 hips with a mean follow-up of 34 months found poor results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/69\">",
"     69",
"    </a>",
"    ]. Only 23 percent achieved satisfactory clinical results, with a Harris Hip Score (a composite measure of pain, function, and physical outcomes) greater than 80 points [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/70\">",
"     70",
"    </a>",
"    ]. With follow-up ranging from 20 months to 10 years, radiographs on 559 hips showed no progression in 26 percent; 174 of 219 hips required replacement.",
"   </p>",
"   <p>",
"    In a study of 248 knees in 136 patients with osteonecrosis, 41 symptomatic knees were initially treated nonoperatively, with progression to advanced radiologic stages occurring in 80 percent of the knees [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/71\">",
"     71",
"    </a>",
"    ]. Similarly, in a retrospective review of 50 hips diagnosed by plain radiographs or bone scans with Ficat stage II, III, or IV osteonecrosis, only three hips (6 percent) remained stable, and none improved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/72\">",
"     72",
"    </a>",
"    ]. Total hip arthroplasty was performed in 34 percent within 16 months.",
"   </p>",
"   <p>",
"    In asymptomatic individuals with early stage osteonecrosis and with limited involvement of the femoral head (ie, &lt;30 percent of the joint surface), healing has been observed in a minority of patients treated nonoperatively. The following are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 13 post-transplant patients with asymptomatic areas of osteonecrosis who were prospectively followed, radiographic healing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      normalization of the MRI took up to one year in the three patients (23 percent) who healed with nonoperative management [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/73\">",
"       73",
"      </a>",
"      ]. Notably, none of the lesions resolved when the contralateral hip had symptomatic disease.",
"     </li>",
"     <li>",
"      Among 40 hips in individuals with asymptomatic stage I disease that affected less than 10 percent of the volume of the femoral head, 11 hips (27 percent) did not progress to collapse during observation of up to 10 years&rsquo; duration [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/74\">",
"       74",
"      </a>",
"      ]. The mean time to develop symptoms was 80 months, and the mean time to collapse was 92 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no consensus on the appropriate treatment of patients with asymptomatic osteonecrosis. Some authorities have suggested that patients with lesions affecting less than 15 percent of the volume of the femoral are best managed nonoperatively, that those with lesions greater than 30 percent should be managed expectantly with anticipation of eventual total hip arthroplasty, and that those with lesions of intermediate size (ie, between 15 and 30 percent) should be managed surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slowing resorption of necrotic bone with bisphosphonates may be beneficial, but the evidence is mixed. In an uncontrolled study of 294 patients (395 involved hips), the aminobisphosphonate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was administered for three years; its use was associated with a decrease in pain and with a progression of femoral head collapse that was slower than expected from historic experience with conservatively treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/75\">",
"     75",
"    </a>",
"    ]. Patients also received 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of calcium and 400 to 800 international",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    of vitamin D3. At a mean follow-up of four years, only 31 hips had required total hip arthroplasty (THA), and there was improvement in pain, disability, standing time, and walking time. However, this improvement did not appear to last in those followed for eight years. It is not known whether treatment with alendronate for greater than three years or the use of other agents is warranted to prevent decline and need for THA.",
"   </p>",
"   <p>",
"    A beneficial effect was also noted in a study that randomly assigned 40 patients (54 affected hips) who had stage II or III osteonecrosis (ON) (University of Pennsylvania classification system) involving &ge;30 percent of the femoral head to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (70",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    for 25 weeks) or nonoperative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/76\">",
"     76",
"    </a>",
"    ]. In this controlled but unblinded study, the proportion of hips that developed collapse was significantly smaller in those who received alendronate than in the controls (2 of 29 [7 percent] versus 19 of 25 [76 percent], respectively). Whether the use of alendronate prevents or only delays collapse is uncertain. Long-term observation of outcomes in alendronate-treated patients is anticipated.",
"   </p>",
"   <p>",
"    Less optimistic reports include a two-year randomized trial in which patients with osteonecrosis received either oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/77\">",
"     77",
"    </a>",
"    ]. There were no significant differences observed in the outcomes between these two groups. Twenty-one of 32 of the patients receiving bisphosphonates progressed radiologically, with four patients undergoing total hip replacement. This was similar to the results of the placebo group with progression noted in 21 of 32 patients and with five patients undergoing total hip replacement. Another trial found that there was no difference in the results between patients with osteonecrosis of the hip receiving shockwave therapy alone compared with those receiving shockwave therapy together with bisphosphonate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Joint-preserving procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The failure of nonoperative management and initial relatively poor long-term survival of prosthetic devices created the need for other interventions aimed at preserving the femoral head and at slowing or halting the progression of osteonecrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Core decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Core decompression was initially used as a diagnostic tool to measure bone marrow pressure and to obtain biopsy specimens. It became a mode of therapy when it was noted that patients had pain relief following the procedure.",
"   </p>",
"   <p>",
"    Numerous small case series and retrospective studies looking at core decompression have been reported; few randomized controlled trials have been performed. In one prospective randomized trial that compared core decompression with nonoperative treatment of 55 hips in 36 patients with osteonecrosis, success (as judged by the Harris Hip Score) was achieved in 7 of 10 surgically treated Ficat stage I hips compared with one of five nonoperatively treated hips at this stage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/79\">",
"     79",
"    </a>",
"    ]. Success was also higher with surgery in stage II hips (five of seven versus zero of seven) and in stage III hips (8 of 11 versus 1 of 10). Stage 0 and IV groups were too small to analyze differences. Less successful results were seen if roentgenographic criteria of success were used.",
"   </p>",
"   <p>",
"    A second randomized trial of 37 hips in 33 patients randomized to core decompression or to nonoperative treatment found that pain relief was significantly better by the first follow-up in the core decompression group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/80\">",
"     80",
"    </a>",
"    ]. However, no statistical difference was found between the groups for the time to collapse.",
"   </p>",
"   <p>",
"    Core decompression for osteonecrosis of the shoulder has not been subjected to prospective, well-designed studies. A retrospective report describing core decompression of 95 shoulders with osteonecrosis reported &ldquo;good to excellent clinical outcomes&rdquo; in 74 (78 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/81\">",
"     81",
"    </a>",
"    ]. Of those shoulders with Ficat and Arlet radiographic stage I, II, III, or IV osteonecrosis, symptomatic relief after decompression was noted in 94, 92, 71, and 13 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Vascularized fibular graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascularized fibular grafting was popularized in the 1990s as an approach that not only provided structural support to the subchondral bone but that also provided a source of mesenchymal stem cells and a vascular supply to the necrotic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/82\">",
"     82",
"    </a>",
"    ]. With a minimum follow-up of five years, survivorship of the graft for stage II, III, IV, and V hips (Marcus and Enneking classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/65\">",
"     65",
"    </a>",
"    ]) was 89, 77, 71, and 73 percent, respectively. A subsequent study found that, of Ficat stage II and III hips followed for at least 10 years, only 13 of 76 (17 percent) were converted to total hip arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/83\">",
"     83",
"    </a>",
"    ]. The results in another study showed that vascularized fibular grafts were dramatically better for Ficat stage III disease than core decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2509439\">",
"    <span class=\"h3\">",
"     Nonvascularized bone grafting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonvascularized bone grafting has also been used in numerous studies with variable success rates. Light-bulk procedures have subsequently shown greater efficacy, although there is still a lack of prospective randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Bone marrow grafting",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has also been increasing and considerable interest in the use of cell-based therapy for the treatment of osteonecrosis. Several reports from Europe have noted improved survivorship when compared with core decompression alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Both autologous and allogenous sources of bone marrow cells are being investigated. The outcomes are too preliminary to make a recommendation .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Osteotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteotomy has also been used as a joint-sparing technique to treat osteonecrosis. The goal of this procedure is to move the area of necrosis away from the major load-transmitting area of the acetabulum and to redistribute the weightbearing forces to articular cartilage, which is supported by healthy bone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/3\">",
"     3",
"    </a>",
"    ]. There are a variety of techniques by which this may be accomplished, several of which are technically demanding.",
"   </p>",
"   <p>",
"    Results of clinical trials utilizing osteotomy vary; the best outcomes have been reported in the Japanese literature. In one report, osteotomy was performed in 128 hips of 90 patients who were then followed for two to nine years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/87\">",
"     87",
"    </a>",
"    ]. Excellent results were obtained clinically and radiographically in 98 hips; the success rate was 90 percent in stage I or II hips. Progressive collapse in the newly created weightbearing area occurred in 25 hips in which the lesions had been extensive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Decompression versus osteotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Core decompression and osteotomy may have similar efficacy in early disease, but intertrochanteric osteotomy may be preferred for patients who have progressed to collapse of the femoral head by the time of diagnosis. This was illustrated in a study of the two techniques in a cohort of 177 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/88\">",
"     88",
"    </a>",
"    ]. Core decompressions were performed on 94 patients, and intertrochanteric osteotomies were performed on 83. Failure of the initial procedure, as indicated by the need for any further hip surgery, occurred in similar proportions of those with early (pre-collapse) disease (26 versus 22 percent). In contrast, failure was more likely following core decompression in those with more advanced disease; for those with collapse of the femoral head at the time of initial surgery, the failure rates were 44 percent with core decompression versus 24 percent with osteotomy. These findings are biologically plausible since core decompression would not be expected to be as effective once collapse had occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Total joint replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of total hip replacement (THR) for the treatment of osteonecrosis are improving. Most older studies suggested a poorer prognosis for patients with osteonecrosis than for other disorders, with failures being three to four times more common. A retrospective review conducted in 1989, for example, compared total hip replacement of 29 hips in 23 patients with osteonecrosis with the same procedure in 63 hips affected by osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/89\">",
"     89",
"    </a>",
"    ]. The revision rate was much higher in the osteonecrosis group (28 versus 6 percent), and the time to revision was an average of five years less in these patients. On the other hand, hip scores following surgery were significantly better in the osteoarthritis group. These findings were in contrast to the findings in other studies of no significant differences between the outcomes for these two patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2011 systematic review of total hip replacement for osteonecrosis, the revision rates were found to have decreased from 17 percent when operations occurred before 1990 to 3 percent when operations occurred in 1990 or later [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/91\">",
"     91",
"    </a>",
"    ]. Further studies of THR using uncemented and cemented femoral components have indicated excellent long-term results for patients with osteonecrosis that are comparable to results for patients with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. The primary cause for re-revision surgery is loss of fixation of the acetabular component secondary to wear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total knee arthroplasty is an option in patients who have osteonecrosis affecting this joint. Similar to that of total hip arthroplasty, the success rate may be lower in patients who have osteonecrosis than in those who receive joint replacement for other reasons. Several studies have demonstrated excellent outcomes in this patient population. A 2006 systematic review noted that the results for patients after 1985 were significantly improved compared with patients prior to 1985, including a revision rate of 3 versus 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total joint arthroplasty may also be utilized for osteonecrosis of the shoulder. In a retrospective analysis, 14 of 16 patients had a successful outcome when assessed four years after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/81\">",
"     81",
"    </a>",
"    ]. These patients either had modified Ficat and Arlet stage IV osteonecrosis or had failed nonoperative treatment or core decompression",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other modalities have been explored to treat osteonecrosis, including the use of electrical stimulation by direct current, of capacitive coupling or pulsed electromagnetic fields, and of pharmacologic agents such as ergoloids, naftidrofuryl, and vincamine aimed at reducing bone marrow pressure. None has met with great success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for osteonecrosis has not been determined. Analyzing the existing data regarding therapy is difficult since most studies are small and retrospective. There are few prospective studies, and, given the progressive nature of the process, untreated controls are not possible. In addition to the size of the studies, differences in staging schemes, proposed associated risk factors of enrolled patients, and quantification of clinical and radiographic responses are not standardized. The treatment also depends upon the particular region affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Osteonecrosis of the femoral head",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the available data, the following recommendations can be made concerning osteonecrosis of the femoral head:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic lesions of the femur that involve less than 15 percent of the femoral head may resolve without surgical intervention and may, therefore, be treated nonoperatively.",
"     </li>",
"     <li>",
"      Asymptomatic lesions that involve more than 30 percent of the femoral head are likely to progress to collapse despite surgical intervention; thus, these patients may also be nonoperatively managed at the outset with anticipation of the eventual need for total hip arthroplasty.",
"     </li>",
"     <li>",
"      In early stage 0 to II lesions (defined using the ARCO classification system) in young active patients, core decompression is the most conservative surgical procedure that offers the best chance at preserving the femoral head. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Clinical staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In later stage II lesions with cyst formation or large lesions and in stage III disease (defined using the ARCO classification system), osteotomy, nonvascularized bone grafting, and vascularized bone grafting are feasible options. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Clinical staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom collapse has occurred and in whom there is acetabular involvement and in older sedentary patients with less severe disease, total hip replacement is the treatment of choice, but only when symptoms justify the surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Total hip replacement has high failure rates in patients with osteonecrosis due to sickle cell disease. Treatment with core decompression or cementation has been reported to be effective early in the course of osteonecrosis in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13728325\">",
"    <span class=\"h2\">",
"     Osteonecrosis of the knee",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the femoral head, the knee is the second most frequent location for secondary osteonecrosis (approximately 10 percent of the incidence of the hip). Treatment recommendations often depend upon distinguishing between three pathologic disorders: secondary osteonecrosis, spontaneous osteonecrosis of the knee (SPONK), and post-arthroscopic osteonecrosis. In our opinion, the treatment approach should differ between these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial management of SPONK and post-arthroscopic ON is to manage nonsurgically. In contrast, nonsurgical management is not recommended for secondary osteonecrosis, because approximately 80 percent of these patients will have progressed to needing a total knee arthroplasty within six years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Joint-preserving procedures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Core decompression or percutaneous drilling, which is effective for the treatment of secondary",
"      <sup>",
"      </sup>",
"      osteonecrosis. One study noted that 92 percent of the knees had a successful outcome, based upon the Knee Society Score greater than 80 points [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/101\">",
"       101",
"      </a>",
"      ], and that total knee replacement was avoided in 59 knees (97 percent) at a mean follow-up of three years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/102\">",
"       102",
"      </a>",
"      ]. The procedures were more successful in the treatment of smaller lesions compared with larger lesions (100 versus 86 percent).",
"     </li>",
"     <li>",
"      Bone grafting of the lesion, which has also been used to treat small- to medium-sized lesions. Outcomes for patients treated with impaction grafting have demonstrated promising results [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/103\">",
"       103",
"      </a>",
"      ]. The objective Knee Society Score after a mean follow-up of approximately four years (range of two to eight years) was 89 (range of 70 to 100), and the functional score was 81 (range of 50 to 100). None of the patients were revised. One study reported that a graft matrix of allogeneic cancellous bone chips augmented with enriched autogenous bone marrow aspirate yielded promising results in three patients with large lesions at two years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite early intervention with joint-preserving procedures, secondary osteonecrosis often proceeds to degeneration of the joint requiring arthroplasty. Both unicompartmental and total knee arthroplasties may be performed. In a study comparing total knee replacement (TKR) before and after 1985, significant improvement in outcome results was noted for TKR after 1985 with 97 percent of patients having a good outcome as indicated by clinician-based assessments and by a 3 percent revision rate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Osteonecrosis of the humeral head",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no randomized trial concerning management of humeral head osteonecrosis has been performed, the available data support the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In those with lesions of stage III or less (defined using the Cruess classification system [",
"      <a class=\"abstract\" href=\"UTD.htm?27/43/28346/abstract/105\">",
"       105",
"      </a>",
"      ]), a trial of nonoperative therapy for up to three months is a reasonable initial option.",
"     </li>",
"     <li>",
"      Core decompression is the best option in patients who do not respond to conservative therapy.",
"     </li>",
"     <li>",
"      In those with stage IV lesions and in those who have less severe radiographic disease but continued symptoms, total shoulder arthroplasty is the treatment of choice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/46/23266?source=see_link\">",
"       \"Patient information: Aseptic necrosis of the hip (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18899908\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteonecrosis is a pathologic process that has been associated with trauma, with numerous atraumatic conditions, and with therapeutic interventions (",
"      <a class=\"graphic graphic_table graphicRef69502 \" href=\"UTD.htm?38/56/39819\">",
"       table 1",
"      </a>",
"      ), most commonly corticosteroid use and excessive alcohol intake. Compromise of the bone vasculature, leading to the death of bone and marrow cells (bone marrow infarction), and ultimate mechanical failure appear to be the common etiologies shared by the varied proposed causes. The mean age at diagnosis is less than 40 years. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18899891\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with prolonged high doses of corticosteroids appear to be at substantial risk of developing osteonecrosis; however, these patients often have multiple other risk factors, particularly systemic lupus erythematosus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Corticosteroids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic lupus erythematosus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early diagnosis of osteonecrosis may provide the opportunity to prevent collapse and the need for joint replacement. However, most patients present late in the course of the disease, and a high index of suspicion is necessary for those with risk factors, particularly high-dose corticosteroid use. The most common presenting symptom of osteonecrosis is pain, although a small proportion of patients are asymptomatic. Physical findings are largely nonspecific. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Pain'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Asymptomatic patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The features of osteonecrosis seen on imaging studies are helpful diagnostically and provide the basis for classification and staging systems. Evaluation for suspected osteonecrosis of the femoral head should begin with anterior-posterior and frog-leg lateral films. The plain radiograph can remain normal for months after symptom onset. The earliest findings are mild density changes, followed by sclerosis and cysts; the pathognomonic crescent sign (subchondral radiolucency) from subchondral collapse; and subsequent loss of sphericity or collapse of the femoral head with eventual joint-space narrowing and degenerative changes in the acetabulum that are visible. Radionuclide bone scanning has moderate sensitivity but is nonspecific. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Plain film radiography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Radionuclide bone scanning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) is far more sensitive than plain radiographs or radionuclide bone scanning and is preferred for diagnostic use in patients with nondiagnostic plain radiography. MRI changes include well-demarcated and inhomogeneous focal lesions on T-1 weighted images with a single density line separating normal and ischemic bone, a well as a second high intensity line on T-2 weighted images (the pathognomonic double-line sign) representing hypervascular granulation tissue. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'MR imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinical diagnosis is appropriately made in a symptomatic patient when imaging findings are compatible with this disease and when other causes of pain and bony abnormalities either are unlikely or have been excluded. (See",
"      <a class=\"local\" href=\"#H119498333\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of osteonecrosis of the hip includes bone marrow edema syndrome and subchondral fracture. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Bone marrow edema syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Subchondral fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classification systems for osteonecrosis may be based upon pathological or radiological findings. However, radiological systems are the most frequently used in the diagnosis, staging, and management of the disease. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Classification systems and staging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Pathologic staging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Clinical staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal management approach for osteonecrosis remains uncertain and controversial. The goal of therapy is to preserve the native joint for as long as possible. The three main therapeutic options include nonoperative management, joint-preserving procedures, and joint replacement. Factors influencing the choice of therapy include the presence (or absence) of symptoms, the degree of involvement, the stage of the lesion, and the comorbidities. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Treatment options'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H47\">",
"       'Treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/1\">",
"      Rajpura A, Wright AC, Board TN. Medical management of osteonecrosis of the hip: a review. Hip Int 2011; 21:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/2\">",
"      Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 2006; 88:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/3\">",
"      Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 1995; 77:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/4\">",
"      Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/5\">",
"      Chang CC, Greenspan A, Gershwin ME. Osteonecrosis: current perspectives on pathogenesis and treatment. Semin Arthritis Rheum 1993; 23:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/6\">",
"      Shigemura T, Nakamura J, Kishida S, et al. Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatology (Oxford) 2011; 50:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/7\">",
"      Gladman DD, Chaudhry-Ahluwalia V, Iba&ntilde;ez D, et al. Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol 2001; 28:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/8\">",
"      Kamen DL, Alele JD. Skeletal manifestations of systemic autoimmune diseases. Curr Opin Endocrinol Diabetes Obes 2010; 17:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/9\">",
"      Jones JP Jr. Fat embolism and osteonecrosis. Orthop Clin North Am 1985; 16:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/10\">",
"      Solomon L. Idiopathic necrosis of the femoral head: pathogenesis and treatment. Can J Surg 1981; 24:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/11\">",
"      Nishimura T, Matsumoto T, Nishino M, Tomita K. Histopathologic study of veins in steroid treated rabbits. Clin Orthop Relat Res 1997; :37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/12\">",
"      Vreden SG, Hermus AR, van Liessum PA, et al. Aseptic bone necrosis in patients on glucocorticoid replacement therapy. Neth J Med 1991; 39:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/13\">",
"      Zizic TM, Marcoux C, Hungerford DS, et al. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985; 79:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/14\">",
"      Abeles M, Urman JD, Rothfield NF. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med 1978; 138:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/15\">",
"      Matsuo K, Hirohata T, Sugioka Y, et al. Influence of alcohol intake, cigarette smoking, and occupational status on idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 1988; :115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/16\">",
"      Fukushima W, Fujioka M, Kubo T, et al. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 2010; 468:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/17\">",
"      Shigemura T, Nakamura J, Kishida S, et al. The incidence of alcohol-associated osteonecrosis of the knee is lower than the incidence of steroid-associated osteonecrosis of the knee: an MRI study. Rheumatology (Oxford) 2012; 51:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/18\">",
"      Dimant J, Ginzler EM, Diamond HS, et al. Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE. J Rheumatol 1978; 5:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/19\">",
"      Sugano N, Ohzono K, Masuhara K, et al. Prognostication of osteonecrosis of the femoral head in patients with systemic lupus erythematosus by magnetic resonance imaging. Clin Orthop Relat Res 1994; :190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/20\">",
"      Aranow C, Zelicof S, Leslie D, et al. Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol 1997; 24:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/21\">",
"      Mont MA, Glueck CJ, Pacheco IH, et al. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 1997; 24:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/22\">",
"      Asherson RA, Liot&eacute; F, Page B, et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1993; 20:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/23\">",
"      Mok MY, Farewell VT, Isenberg DA. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 2000; 59:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/24\">",
"      Jones LC, Mont MA, Le TB, et al. Procoagulants and osteonecrosis. J Rheumatol 2003; 30:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/25\">",
"      Vasoo S, Sangle S, Zain M, et al. Orthopaedic manifestations of the antiphospholipid (Hughes) syndrome. Lupus 2005; 14:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/26\">",
"      PHEMISTER DB. Treatment of the necrotic head of the femur in adults. J Bone Joint Surg Am 1949; 31A:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/27\">",
"      Almquist EE. Kienbock's disease. Clin Orthop Relat Res 1986; :68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/28\">",
"      Goldblatt J, Sacks S, Beighton P. The orthopedic aspects of Gaucher disease. Clin Orthop Relat Res 1978; :208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/29\">",
"      Miyanishi K, Kamo Y, Ihara H, et al. Risk factors for dysbaric osteonecrosis. Rheumatology (Oxford) 2006; 45:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/30\">",
"      Ibels LS, Alfrey AC, Huffer WE, Weil R 3rd. Aseptic necrosis of bone following renal transplantation: experience in 194 transplant recipients and review of the literature. Medicine (Baltimore) 1978; 57:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/31\">",
"      Metselaar HJ, van Steenberge EJ, Bijnen AB, et al. Incidence of osteonecrosis after renal transplantation. Acta Orthop Scand 1985; 56:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/32\">",
"      Lopez-Ben R, Mikuls TR, Moore DS, et al. Incidence of hip osteonecrosis among renal transplantation recipients: a prospective study. Clin Radiol 2004; 59:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/33\">",
"      Nehme D, Rondeau E, Paillard F, et al. Aseptic necrosis of bone following renal transplantation: relation with hyperparathyroidism. Nephrol Dial Transplant 1989; 4:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/34\">",
"      Tauchmanov&agrave; L, De Rosa G, Serio B, et al. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer 2003; 97:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/35\">",
"      Schulte CM, Beelen DW. Avascular osteonecrosis after allogeneic hematopoietic stem-cell transplantation: diagnosis and gender matter. Transplantation 2004; 78:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/36\">",
"      Zalavras CG, Vartholomatos G, Dokou E, Malizos KN. Factor V Leiden and prothrombin gene mutations in femoral head osteonecrosis. Thromb Haemost 2002; 87:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/37\">",
"      Arruda VR, Belangero WD, Ozelo MC, et al. Inherited risk factors for thrombophilia among children with Legg-Calv&eacute;-Perthes disease. J Pediatr Orthop 1999; 19:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/38\">",
"      Bj&ouml;rkman A, Svensson PJ, Hillarp A, et al. Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res 2004; :168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/39\">",
"      Bj&ouml;rkman A, Burtscher IM, Svensson PJ, et al. Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg 2005; 125:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/40\">",
"      Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/41\">",
"      Martin K, Lawson-Ayayi S, Miremont-Salam&eacute; G, et al. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002). HIV Med 2004; 5:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/42\">",
"      Liu YF, Chen WM, Lin YF, et al. Type II collagen gene variants and inherited osteonecrosis of the femoral head. N Engl J Med 2005; 352:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/43\">",
"      Su P, Li R, Liu S, et al. Age at onset-dependent presentations of premature hip osteoarthritis, avascular necrosis of the femoral head, or Legg-Calv&eacute;-Perthes disease in a single family, consequent upon a p.Gly1170Ser mutation of COL2A1. Arthritis Rheum 2008; 58:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/44\">",
"      Miyamoto Y, Matsuda T, Kitoh H, et al. A recurrent mutation in type II collagen gene causes Legg-Calv&eacute;-Perthes disease in a Japanese family. Hum Genet 2007; 121:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/45\">",
"      Zizic TM, Marcoux C, Hungerford DS, Stevens MB. The early diagnosis of ischemic necrosis of bone. Arthritis Rheum 1986; 29:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/46\">",
"      LaPorte DM, Mont MA, Mohan V, et al. Multifocal osteonecrosis. J Rheumatol 1998; 25:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/47\">",
"      Mont MA, Zywiel MG, Marker DR, et al. The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review. J Bone Joint Surg Am 2010; 92:2165.",
"     </a>",
"    </li>",
"    <li>",
"     Mazieres B. Osteonecrosis. In: Rheumatology, Hochberg MC, Silman AJ, Smolen JS, et al. (Eds), Mosby, London 2003. p.1877.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/49\">",
"      Dumont M, Danais S, Taillefer R. \"Doughnut\" sign in avascular necrosis of the bone. Clin Nucl Med 1984; 9:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/50\">",
"      Mont MA, Ulrich SD, Seyler TM, et al. Bone scanning of limited value for diagnosis of symptomatic oligofocal and multifocal osteonecrosis. J Rheumatol 2008; 35:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/51\">",
"      Markisz JA, Knowles RJ, Altchek DW, et al. Segmental patterns of avascular necrosis of the femoral heads: early detection with MR imaging. Radiology 1987; 162:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/52\">",
"      Guerra JJ, Steinberg ME. Distinguishing transient osteoporosis from avascular necrosis of the hip. J Bone Joint Surg Am 1995; 77:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/53\">",
"      Nagasawa K, Tsukamoto H, Tada Y, et al. Imaging study on the mode of development and changes in avascular necrosis of the femoral head in systemic lupus erythematosus: long-term observations. Br J Rheumatol 1994; 33:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/54\">",
"      Hungerford DS, Jones LC. Asymptomatic osteonecrosis: should it be treated? Clin Orthop Relat Res 2004; :124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/55\">",
"      Ha YC, Jung WH, Kim JR, et al. Prediction of collapse in femoral head osteonecrosis: a modified Kerboul method with use of magnetic resonance images. J Bone Joint Surg Am 2006; 88 Suppl 3:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/56\">",
"      Etienne G, Mont MA, Ragland PS. The diagnosis and treatment of nontraumatic osteonecrosis of the femoral head. Instr Course Lect 2004; 53:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/57\">",
"      Amanatullah DF, Strauss EJ, Di Cesare PE. Current management options for osteonecrosis of the femoral head: part 1, diagnosis and nonoperative management. Am J Orthop (Belle Mead NJ) 2011; 40:E186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/58\">",
"      Davies M, Cassar-Pullicino VN, Darby AJ. Subchondral insufficiency fractures of the femoral head. Eur Radiol 2004; 14:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/59\">",
"      Yamamoto T, Bullough PG. The role of subchondral insufficiency fracture in rapid destruction of the hip joint: a preliminary report. Arthritis Rheum 2000; 43:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/60\">",
"      Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg Br 1985; 67:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/61\">",
"      Berend KR, Gunneson EE, Urbaniak JR. Free vascularized fibular grafting for the treatment of postcollapse osteonecrosis of the femoral head. J Bone Joint Surg Am 2003; 85-A:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/62\">",
"      Ohzono K, Saito M, Sugano N, et al. The fate of nontraumatic avascular necrosis of the femoral head. A radiologic classification to formulate prognosis. Clin Orthop Relat Res 1992; :73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/63\">",
"      Nakamura J, Kishida S, Harada Y, et al. Inter-observer and intra-observer reliabilities of the Japanese Ministry of Health, Labor and Welfare type classification system for osteonecrosis of the femoral head. Mod Rheumatol 2011; 21:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/64\">",
"      Steinberg ME, Brighton CT, Corces A, et al. Osteonecrosis of the femoral head. Results of core decompression and grafting with and without electrical stimulation. Clin Orthop Relat Res 1989; :199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/65\">",
"      Marcus ND, Enneking WF, Massam RA. The silent hip in idiopathic aseptic necrosis. Treatment by bone-grafting. J Bone Joint Surg Am 1973; 55:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/66\">",
"      Steinberg ME, Bands RE, Parry S, et al. Does lesion size affect the outcome in avascular necrosis? Clin Orthop Relat Res 1999; :262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/67\">",
"      Stulberg BN, Singer R, Goldner J, Stulberg J. Uncemented total hip arthroplasty in osteonecrosis: a 2- to 10-year evaluation. Clin Orthop Relat Res 1997; :116.",
"     </a>",
"    </li>",
"    <li>",
"     ARCO staging system for osteonecrosis. file://arco-intl.org/Newsletters/Gardeniers-1993-5-2/Gardeniers-1993.htm (Accessed on December 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/69\">",
"      Mont MA, Carbone JJ, Fairbank AC. Core decompression versus nonoperative management for osteonecrosis of the hip. Clin Orthop Relat Res 1996; :169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/70\">",
"      Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am 1969; 51:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/71\">",
"      Mont MA, Baumgarten KM, Rifai A, et al. Atraumatic osteonecrosis of the knee. J Bone Joint Surg Am 2000; 82:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/72\">",
"      Musso ES, Mitchell SN, Schink-Ascani M, Bassett CA. Results of conservative management of osteonecrosis of the femoral head. A retrospective review. Clin Orthop Relat Res 1986; :209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/73\">",
"      Cheng EY, Thongtrangan I, Laorr A, Saleh KJ. Spontaneous resolution of osteonecrosis of the femoral head. J Bone Joint Surg Am 2004; 86-A:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/74\">",
"      Hernigou P, Poignard A, Nogier A, Manicom O. Fate of very small asymptomatic stage-I osteonecrotic lesions of the hip. J Bone Joint Surg Am 2004; 86-A:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/75\">",
"      Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br 2009; 91:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/76\">",
"      Lai KA, Shen WJ, Yang CY, et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 2005; 87:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/77\">",
"      Chen CH, Chang JK, Lai KA, et al. Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012; 64:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/78\">",
"      Wang CJ, Wang FS, Yang KD, et al. Treatment of osteonecrosis of the hip: comparison of extracorporeal shockwave with shockwave and alendronate. Arch Orthop Trauma Surg 2008; 128:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/79\">",
"      Stulberg BN, Davis AW, Bauer TW, et al. Osteonecrosis of the femoral head. A prospective randomized treatment protocol. Clin Orthop Relat Res 1991; :140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/80\">",
"      Koo KH, Kim R, Ko GH, et al. Preventing collapse in early osteonecrosis of the femoral head. A randomised clinical trial of core decompression. J Bone Joint Surg Br 1995; 77:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/81\">",
"      Mont MA, Payman RK, Laporte DM, et al. Atraumatic osteonecrosis of the humeral head. J Rheumatol 2000; 27:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/82\">",
"      Urbaniak JR, Coogan PG, Gunneson EB, Nunley JA. Treatment of osteonecrosis of the femoral head with free vascularized fibular grafting. A long-term follow-up study of one hundred and three hips. J Bone Joint Surg Am 1995; 77:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/83\">",
"      Yoo MC, Kim KI, Hahn CS, Parvizi J. Long-term followup of vascularized fibular grafting for femoral head necrosis. Clin Orthop Relat Res 2008; 466:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/84\">",
"      Scully SP, Aaron RK, Urbaniak JR. Survival analysis of hips treated with core decompression or vascularized fibular grafting because of avascular necrosis. J Bone Joint Surg Am 1998; 80:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/85\">",
"      Gangji V, Hauzeur JP, Matos C, et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am 2004; 86-A:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/86\">",
"      Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 2002; :14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/87\">",
"      Sugioka Y, Katsuki I, Hotokebuchi T. Transtrochanteric rotational osteotomy of the femoral head for the treatment of osteonecrosis. Follow-up statistics. Clin Orthop Relat Res 1982; :115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/88\">",
"      Simank HG, Brocai DR, Brill C, Lukoschek M. Comparison of results of core decompression and intertrochanteric osteotomy for nontraumatic osteonecrosis of the femoral head using Cox regression and survivorship analysis. J Arthroplasty 2001; 16:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/89\">",
"      Saito S, Saito M, Nishina T, et al. Long-term results of total hip arthroplasty for osteonecrosis of the femoral head. A comparison with osteoarthritis. Clin Orthop Relat Res 1989; :198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/90\">",
"      Ritter MA, Meding JB. A comparison of osteonecrosis and osteoarthritis patients following total hip arthroplasty. A long-term follow-up study. Clin Orthop Relat Res 1986; :139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/91\">",
"      Johannson HR, Zywiel MG, Marker DR, et al. Osteonecrosis is not a predictor of poor outcomes in primary total hip arthroplasty: a systematic literature review. Int Orthop 2011; 35:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/92\">",
"      Hungerford MW, Hungerford DS, Jones LC. Outcome of uncemented primary femoral stems for treatment of femoral head osteonecrosis. Orthop Clin North Am 2009; 40:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/93\">",
"      Kim YH, Oh SH, Kim JS, Koo KH. Contemporary total hip arthroplasty with and without cement in patients with osteonecrosis of the femoral head. J Bone Joint Surg Am 2003; 85-A:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/94\">",
"      Solarino G, Piazzolla A, Notarnicola A, et al. Long-term results of 32-mm alumina-on-alumina THA for avascular necrosis of the femoral head. J Orthop Traumatol 2012; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/95\">",
"      Kim YH, Kim JS, Park JW, Joo JH. Contemporary total hip arthroplasty with and without cement in patients with osteonecrosis of the femoral head: a concise follow-up, at an average of seventeen years, of a previous report. J Bone Joint Surg Am 2011; 93:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/96\">",
"      Myers TG, Cui Q, Kuskowski M, et al. Outcomes of total and unicompartmental knee arthroplasty for secondary and spontaneous osteonecrosis of the knee. J Bone Joint Surg Am 2006; 88 Suppl 3:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/97\">",
"      Styles LA, Vichinsky EP. Core decompression in avascular necrosis of the hip in sickle-cell disease. Am J Hematol 1996; 52:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/98\">",
"      Hernigou P, Bachir D, Galacteros F. Avascular necrosis of the femoral head in sickle-cell disease. Treatment of collapse by the injection of acrylic cement. J Bone Joint Surg Br 1993; 75:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/99\">",
"      Mont MA, Marker DR, Zywiel MG, Carrino JA. Osteonecrosis of the knee and related conditions. J Am Acad Orthop Surg 2011; 19:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/100\">",
"      Mont MA, Tomek IM, Hungerford DS. Core decompression for avascular necrosis of the distal femur: long term followup. Clin Orthop Relat Res 1997; :124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/101\">",
"      Insall JN, Dorr LD, Scott RD, Scott WN. Rationale of the Knee Society clinical rating system. Clin Orthop Relat Res 1989; :13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/102\">",
"      Marulanda G, Seyler TM, Sheikh NH, Mont MA. Percutaneous drilling for the treatment of secondary osteonecrosis of the knee. J Bone Joint Surg Br 2006; 88:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/103\">",
"      Rijnen WH, Luttjeboer JS, Schreurs BW, Gardeniers JW. Bone impaction grafting for corticosteroid-associated osteonecrosis of the knee. J Bone Joint Surg Am 2006; 88 Suppl 3:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/104\">",
"      Lee K, Goodman SB. Cell therapy for secondary osteonecrosis of the femoral condyles using the Cellect DBM System: a preliminary report. J Arthroplasty 2009; 24:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/43/28346/abstract/105\">",
"      Cruess RL. Steroid-induced avascular necrosis of the head of the humerus. Natural history and management. J Bone Joint Surg Br 1976; 58:313.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5613 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28346=[""].join("\n");
var outline_f27_43_28346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18899908\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18899891\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sickle cell hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gaucher disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Decompression disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H435805\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Plain film radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Radionuclide bone scanning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - MR imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H119498333\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Bone marrow edema syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Subchondral fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      CLASSIFICATION SYSTEMS AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Pathologic staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Clinical staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194050126\">",
"      Nonoperative treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Joint-preserving procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Core decompression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Vascularized fibular graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2509439\">",
"      - Nonvascularized bone grafting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Bone marrow grafting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Osteotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Decompression versus osteotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Total joint replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Osteonecrosis of the femoral head",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13728325\">",
"      Osteonecrosis of the knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Osteonecrosis of the humeral head",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18899908\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5613\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5613|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/34/1583\" title=\"diagnostic image 1A\">",
"      Osteonecrosis of hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/5/19551\" title=\"diagnostic image 1B\">",
"      Osteonecrosis femoral head",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/7/17523\" title=\"diagnostic image 2\">",
"      Osteonecrosis of knee MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/59/32702\" title=\"diagnostic image 3\">",
"      Osteonecrosis hips plain film",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5613|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39819\" title=\"table 1\">",
"      Etiology of osteonecrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18506?source=related_link\">",
"      Bone and joint complications in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=related_link\">",
"      Evaluation of bone marrow aspirate smears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=related_link\">",
"      Evaluation of the adult with hip pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=related_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=related_link\">",
"      Overview of hip pain in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/46/23266?source=related_link\">",
"      Patient information: Aseptic necrosis of the hip (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=related_link\">",
"      Radiologic evaluation of the painful hip in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_43_28347="Rabies postexposure prophylaxis";
var content_f27_43_28347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rabies postexposure prophylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccination category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Biologic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Schedule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Not previously vaccinated",
"        </strong>",
"       </td>",
"       <td>",
"        RIG",
"       </td>",
"       <td>",
"        Total dose is 20 units/kg body weight. As much of the full dose as feasible should be infiltrated around the wound(s) and any remaining given IM.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaccine",
"       </td>",
"       <td>",
"        Human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV) 1 mL, IM (deltoid area), 1 each on days 0, 3, 7 and 14*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Previously vaccinated",
"        </strong>",
"       </td>",
"       <td>",
"        RIG",
"       </td>",
"       <td>",
"        Not indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaccine",
"       </td>",
"       <td>",
"        HDCV or PCECV 1 mL, IM (deltoid area), 1 each on days 0 and 3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RIG: rabies immune globulin.",
"     <br>",
"      * For persons with immunosuppression, rabies postexposure prophylaxis should be administered using all five doses of vaccine on days 0, 3, 7, 14, and 28.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2010; 59:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28347=[""].join("\n");
var outline_f27_43_28347=null;
var title_f27_43_28348="DRESS scoring system";
var content_f27_43_28348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Scoring system for classifying drug reactions with eosinophilia and systemic symptoms (DRESS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Item",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Present",
"       </td>",
"       <td class=\"subtitle1\">",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Fever &ge;38.5&deg;C (101.3&deg;F)",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        &minus;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Enlarged lymph nodes (&gt;1 cm size, at least two sites)",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilia: &ge;700 or &ge;10 percent (leucopenia)",
"       </td>",
"       <td>",
"        &ge;1500 or &ge;20 percent (leucopenia)",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Atypical lymphocytes",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Rash &ge;50 percent of body surface area",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Rash suggestive (&ge;2 of facial edema, peripheral edema, infiltration, desquamation)",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Skin biopsy suggesting alternative diagnosis",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        &minus;1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organ involvement: one",
"       </td>",
"       <td>",
"        two or more",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Disease duration &gt;15 days",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        &minus;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Investigation for alternative cause (blood cultures, ANA, serology for Hepatitis viruses, mycoplasma, Chlamydia) &ge;3 done and negative",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Total score &lt;2: excluded; 2-3: possible; 4-5: probable; &ge;6: definite.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist? Br J Dermatol 2007; 156:609.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28348=[""].join("\n");
var outline_f27_43_28348=null;
var title_f27_43_28349="CF nutrition tests";
var content_f27_43_28349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory monitoring of nutritional status for children with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Recommended frequency",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        At diagnosis",
"       </td>",
"       <td class=\"subtitle2\">",
"        Annually",
"       </td>",
"       <td class=\"subtitle2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta carotene",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        At physician's discretion",
"       </td>",
"       <td>",
"        Serum levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin A",
"       </td>",
"       <td class=\"centered\">",
"        X*",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        Also check serum retinol binding protein and retinyl esters in patients with liver disease",
"       </td>",
"       <td>",
"        Vitamin A (retinol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin D",
"       </td>",
"       <td class=\"centered\">",
"        X*",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25-OH-D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin E",
"       </td>",
"       <td class=\"centered\">",
"        X*",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &alpha;-tocopherol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin K",
"       </td>",
"       <td class=\"centered\">",
"        X*",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        If patient has hemoptysis or hematemesis; in patients with liver disease",
"       </td>",
"       <td>",
"        PIVKA-II (preferably) or prothrombin time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Essential fatty acids",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Consider checking in infants or those with FTT",
"       </td>",
"       <td>",
"        <p>",
"         Triene:tetraene ratio",
"        </p>",
"        or Linoleic acid (as moles percent of total serum phospholipid fatty acids)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium/bone status",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        Begin DXA at age 8 years if risk factors are present",
"        <sup>",
"         &bull;",
"        </sup>",
"        and repeat every 1 to 2 years depending on results (see text)",
"       </td>",
"       <td>",
"        Calcium, phosphorus, intact PTH, DXA scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        Consider in-depth evaluation for patients with poor appetite",
"       </td>",
"       <td>",
"        <p>",
"         Hemoglobin, hematocrit",
"        </p>",
"        Serum transferrin receptor (sTfR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Consider 6-month supplementation trial and follow growth",
"       </td>",
"       <td>",
"        No acceptable measurement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Consider checking if exposed to heat stress and becomes dehydrated",
"       </td>",
"       <td>",
"        Serum sodium; spot urine sodium if total body sodium depletion suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein stores",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        Check in patients with nutritional failure or those at risk",
"       </td>",
"       <td>",
"        Albumin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral glucose tolerance test",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        HgbA1c &ge;6.5 percent or fasting plasma glucose &ge;126 mg/dL support the diagnosis of CFRD but are not sufficiently sensitive to use for screening",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     25-OH-D: 25-hydroxyvitamin D; PIVKA: proteins induced by vitamin K absence or antagonism; FTT: failure to thrive; Intact PTH: intact parathyroid hormone; DXA: dual energy x-ray absorptiometry; HgbA1c: hemoglobin A1c.",
"     <br/>",
"     * For infants diagnosed by neonatal screening these should be measured approximately 2 months after starting vitamin supplementation, and annually thereafter.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Risk factors for bone disease include body mass index (BMI) &lt;10th percentile for age, FEV1 &lt;50 percent predicted, glucocorticoid use of &ge;5 mg daily for &ge;90 days/year, delayed puberty, or a history of fractures.",
"     <br/>",
"     &Delta; Testing for cystic fibrosis-related diabetes (CFRD) using the oral glucose tolerance test (OGTT) should be performed annually in patients 10 years and older, and also in patients who develop symptoms of CFRD.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35:246. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"     <br/>",
"     Additional recommendations on bone health from: Aris RM, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90:1888.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28349=[""].join("\n");
var outline_f27_43_28349=null;
var title_f27_43_28350="Ferrous sulfate overdose";
var content_f27_43_28350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal radiograph in iron overdose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 215px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal radiograph showing radiopaque iron (ferrous sulfate) tablets visualized in the stomach of an intentional overdose patient (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Burns, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28350=[""].join("\n");
var outline_f27_43_28350=null;
var title_f27_43_28351="Posterior vaginal wall prolapse 5";
var content_f27_43_28351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of a left lateral defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_43_28351=[""].join("\n");
var outline_f27_43_28351=null;
